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Abstract
Bacterial pneumonia, one of the leading causes of hospitalization and mortality
worldwide, is caused by the colonization of invasive bacteria in the airways, leading to
pulmonary inflammation and lung dysfunction. The development of antibiotic resistant
bacterial infections has limited the effectiveness of current therapeutics and is particularly
concerning in the setting of chronic bacterial infections, such as observed in cystic fibrosis
and ventilator-associated pneumonia. The development of novel therapeutics for the
treatment of multi-drug resistant bacterial pneumonia is urgently needed.
The overall objective of this body of work was the development of a new
therapeutic compound to treat multi-drug resistant bacterial infections in the lung. It was
hypothesized that a cathelicidin/exogenous surfactant compound could be developed as a
novel therapeutic agent for the treatment of bacterial pneumonia. To test this hypothesis,
we first screened several cathelicidin peptides combined with a commercial exogenous
surfactant, bovine lipid extract surfactant (BLES), and identified a lead compound (CATH2) for further testing. Following this, we investigated three main outcomes: 1) the
antimicrobial activity of CATH-2 and BLES+CATH-2 against multi-drug resistant,
clinically isolated bacteria; 2) the immunomodulatory potential of both CATH-2 and
BLES+CATH-2 in vivo; and 3) the bactericidal activity of BLES+CATH-2 treatment in
vivo, using two models of bacterial pneumonia.
It was discovered that CATH-2 was able to kill bacteria in vitro. In addition, CATH2-killed bacteria administered into the lungs of mice did not induce an inflammatory
response in vivo, and the ability to prevent this inflammation was maintained by
BLES+CATH-2. Finally, while BLES+CATH-2 is able to kill multi-drug resistant,
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clinically derived bacteria in vitro, there is little bactericidal activity of BLES+CATH-2 in
in vivo models of bacterial pneumonia.
Overall, we identified the therapeutic potential of BLES+CATH-2 for use as a
therapeutic treatment for bacterial pneumonia. Despite promising in vitro activity, we were
unable to show bactericidal activity for BLES+CATH-2 in vivo. Future directions will
require the optimization of the surfactant-cathelicidin compound in order to develop a
viable therapeutic for clinical practice.
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Chapter 1: General Introduction and Literature Review

2
Every day, approximately 10 000 L of air will flow into and out of the lungs, and
bring with it foreign particles, such as bacteria, from either the surrounding environment or
the nasopharynx. Due to the unique branching structure of the lung, some of this
particulate-filled air will pass into the terminal bronchioles, respiratory bronchioles, and
alveoli. Over the course of this steady siege, some pathogens are able to circumvent the
innate immune system, leading to colonization and infection of the lung, known as
pneumonia. Pneumonia is one of the most common presentations of bacterial infections,
with millions of people being diagnosed annually (1). It is the leading cause of death due
to infection; estimates by the World Health Organization suggest that bacterial pneumonia
is responsible for 15% of all children deaths under the age of 5, and an estimated 3.2 million
deaths annually (2–5).
Furthermore, the rate of drug-resistant infections is rapidly escalating, and is
becoming a large global health concern. Multi-drug resistant infections are currently
estimated to be responsible for 700 000 deaths per year, with that number expected to rise
to 10 million per year by 2050 without immediate intervention (6). The high prevalence of
pneumonia infection and increasing rates of antibiotic resistant infections are two factors
culminating into a potential global health disaster.
The purpose of this thesis will be to determine the efficacy of a novel therapeutic
for the treatment of multi-drug resistant bacterial pneumonia. Here, we investigate the
development of a potential treatment using a cathelicidin peptide in conjunction with
exogenous surfactant as a vehicle to improve delivery to the respiratory system. This
chapter will provide an overview of homeostatic respiratory functions, pathologic
processes that develop over the course of chronic bacterial respiratory infections in cystic
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fibrosis or mechanical ventilation, and the morbidities of antibiotic resistance associated
with these pulmonary infections. Finally, it will provide an overview of both cathelicidins
and exogenous surfactant, and their therapeutic potential for the treatment of multi-drug
resistant bacterial pneumonia.

1.1 Lung Structure and Function in Homeostatic Conditions
The primary function of the lungs is gas exchange. In the lungs, oxygen diffuses
from the alveoli at the terminal ends of the airways, across epithelia and endothelia, and
into the deoxygenated blood within the surrounding alveolar capillaries; mirroring this,
carbon dioxide moves down its concentration gradient from the blood stream into the
alveoli and is eventually expired out of the body (Reviewed in (7)).
The anatomy of the lungs involves a complex branching network, beginning in the
nasopharynx, to the trachea, and then branching into two primary bronchi. From there, the
bronchi will continue to divide into smaller and smaller airways, eventually forming
terminal bronchioles. These structures are involved in air flow, but do not participate in gas
exchange. Distal to the terminal bronchioles are respiratory bronchioles, which are
structurally similar with the exception that they contain budding alveoli that will participate
in gas exchange. Past these respiratory bronchioles are alveolar sacs, containing groups of
alveoli, the primary regions of gas exchange. The complex branching structure allows for
a large surface area at the alveolar level, allowing for rapidly efficient gas exchange with
the surrounding alveolar capillaries (7).
The alveoli themselves are structured by a combination of thin, squamous Type I
alveolar cells and a smaller number of cuboidal Type II alveolar cells. Type I cells are
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essential for gas exchange, as their large surface area and thin structure allows for maximal
diffusion. On the other hand, Type II cells are essential for numerous other functions,
including replenishing Type I cell populations after injury, and producing pulmonary
surfactant, a lipoprotein substance that contributes to breathing mechanics (8, 9). Other
cells within the alveolar space include alveolar macrophages, essential phagocytes tasked
with patrolling the alveoli, engulfing inhaled pathogens and debris particles, and regulating
the innate and adaptive immune system (10–12).
1.1.1 Pulmonary mechanics
To facilitate gas exchange, air flows in and out of the lungs by a process known as
ventilation. This process requires the coordinated contraction of both external intercostal
muscles and the diaphragm to increase the volume of the thoracic cavity. This increased
volume causes a decrease in pressure, as predicted by Boyle’s Law, and causes the
movement of a discrete volume of external air to enter into the lungs, referred to as the tidal
volume. At rest, exhalation is due to the relaxation of these muscles; the decreased thoracic
volume then creates a (relatively) high-pressure environment within the lungs, and air
moves out to the external environment. During exertion, internal intercostals, abdominals,
and oblique muscles will also contract to reduce thoracic cavity volume with greater force,
increasing the volume and rate of exhalation (7).
In addition to the role of the respiratory muscles, there are numerous other processes
within the lungs that affect ventilation. One specific measurement of these mechanics is
lung compliance. Lung compliance refers to the amount of force required to inflate the
lungs. This is calculated as the volume change per unit of pressure change (7). There are
two major factors in the lung responsible for compliance – lung elastic tissue, and surface
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tension within the small airways and alveoli (discussed in section 1.1.2). The elastance of
the lung is proportional to the structural components of the lungs, specifically the amount
of elastin and collagen content within the airway interstitium (7). Increased elastin and
collagen content within the lung leads to reduced compliance, as it increases the force
required to expand the lungs upon inhalation. The surface tension within the lungs has a
major effect on lung function, as increased surface tension has a significant impact on lung
compliance and alveolar stability upon exhalation. Pulmonary surfactant is directly
responsible for reducing the surface tension within the lung.
1.1.2 The pulmonary surfactant system
As noted above, one of the forces responsible for determining lung compliance is
surface tension. The surface tension within the lungs is caused by a thin liquid layer lining
the entire respiratory tract, known as the airway surface liquid (ASL), that begins in the
nasopharynx and extends down to the alveoli. Within the alveoli, the surface tension
exerted by water molecules of the ASL produce an elastic force that reduces compliance.
Pulmonary surfactant is responsible for reducing this force by adsorbing to the air-liquid
interface of the ASL and acting to reduce surface tension during exhalation and inhalation
(13, 14). During exhalation, due to the decreasing size of the alveoli, lateral compression
of the pulmonary surfactant film reduces surface tension to minimal values; this minimizes
any collapse force on the alveoli (14). By reducing surface tension, the collapse force is
reduced, making the lungs easier to inflate. Therefore, reducing surface tension is directly
associated with increased lung compliance.
Pulmonary surfactant is a lipoprotein complex produced and secreted by type II
alveolar cells (9). It is found in all mammalian species and has a highly conserved
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composition (15). It is made up of ~80% lipids by mass, such as phosphatidylcholine (PC,
80%

of

lipid

subfraction)

and

phosphatidylglycerol

(PG,

10-11%

of

lipid

subfraction),~10% neutral lipids, such as cholesterol, and ~10% surfactant associated
proteins, named SP-A, -B, -C, and -D (16). Upon synthesis of these lipid-protein mixtures,
type II cells store surfactant in intracellular structures known as lamellar bodies until
signalled to secrete into the airspace (17, 18). Once secreted, the surfactant will adsorb to
the air-liquid interface to form a surface-active film, which is further discussed below (19,
20). The “functional” components of surfactant are experimentally known as the “large
aggregate”. During repeated cyclic expansions and compressions of the surface film
(throughout the course of respiration), small surfactant vesicles are generated, and then
recycled by resident alveolar macrophages and type II cells; this “inactive” surfactant
component is experimentally referred to as “small aggregate” (21, 22).
While true de novo adsorption only occurs during the first breath at birth, surfactant
secreted into the alveolar liquid lining spreads rapidly along the interface in order to form
the surface-active film responsible for surface tension reduction upon compression.
Surfactant-associated proteins SP-B and SP-C promote the breaking of stable phospholipid
bilayers in the aqueous layer to induce adsorption of lipids to the air-liquid interface. The
rapid diffusion and spreading of the surfactant film allows for the initial reduction of
surface tension in the alveoli, improving lung compliance and alveolar stability (19). After
this first breath, surfactant is cycled into the air-liquid interface over the course of
respiration with the help of SP-B and SP-C, as inactivated surfactant lipids are recycled
back to type II cells or degraded by alveolar macrophages (23).
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Patients with a poorly functioning pulmonary surfactant system, or surfactant
deficient states, typically exhibit a severe decrease in lung compliance, eventually leading
to atelectasis (alveolar collapse) and decreased oxygenation. One such example is neonatal
respiratory distress syndrome (nRDS), where premature infants are born without a fully
developed pulmonary surfactant system (24). Administration of exogenous surfactant to
neonates lacking sufficient pulmonary surfactant has been demonstrated to rapidly improve
compliance, oxygenation, and patient outcomes (25–27). Since its identification as a viable
therapeutic in the 1980’s, exogenous surfactant administration has become a standard
treatment for premature infants diagnosed with nRDS (25, 28). Due to its superior clinical
efficacy and its innate ability to spread throughout the respiratory tract, surfactant has since
been investigated for numerous other therapeutic functions, such as a vehicle for pulmonary
therapy distribution (29, 30).

1.2 Chronic Bacterial Lung Infections
Bacterial pneumonia is an infection of the respiratory tract, and is one of the leading
causes of hospitalization (4, 31–34). Over the course of prolonged infection, the continual
inflammatory environment can precipitate structural changes to the respiratory tract,
eventually resulting in severe decreases in oxygenation and potentially death (35, 36).
Chronic infections associated with cystic fibrosis or mechanical ventilation are two major
examples in which prolonged infections associated with these underlying conditions
increase the complexity of the disease and increase the rate of mortality (4, 35, 37). Typical
treatment strategies for these two diseases involve administration of antibiotics to target the
infection; however, the bacteria are typically incompletely eradicated, and antibiotic use is
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forced to continue over a prolonged period, or to treat acute exacerbations (38). As such,
prolonged administration of antibiotics, without the effective clearance of the colonizing
bacteria, can contribute directly to the high prevalence of antimicrobial resistant infections,
further complicating treatment strategies.
1.2.1 Cystic fibrosis
Cystic fibrosis (CF) is an inherited disease of the cystic fibrosis transmembrane
conductance regulator (CFTR). The development of this disease has been thoroughly
investigated since the initial identification of the CFTR gene (39–41). In these patients, a
non-functioning/hypofunctioning CFTR channel prevents the movement of chloride and
bicarbonate ions into the air surface liquid. Due to the poor movement of ions across the
luminal membrane, there is a decrease in osmotic forces into the lumen, and as a result the
ASL becomes dehydrated and viscous. This highly viscous mucus is unable to properly
detach from the secretory ducts of submucosal glands after secretion (42). To further
compound this problem, the cilia on the apical surface of the airway epithelia become lessfunctional, meaning that any particles or pathogens trapped in the thickened mucus can no
longer be cleared from the airways. These individual factors combine to elicit the bacterialaden mucus plugs characteristic of cystic fibrosis pulmonary disease (43). Combined with
the defect in the mucociliary escalator, studies have also shown that there is a severe
detriment in the innate host defense of recruited cell types as well (44). Decreases in the
pH of the ASL, likely due to the reduction of bicarbonate movement, has been
demonstrated to be responsible for lack of bacterial killing induced by the innate factors
present, including cathelicidins, defensins, and other antimicrobial peptides (44).
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Interestingly, this acidified environment also appears to have an effect on the viscosity of
the ASL itself (45).
The result of these deficiencies allows pathogens to colonize and proliferate, and
without a functioning clearance system, CF patients develop frequent, spontaneous lung
infections of Staphylococcus aureus, Pseudomonas aeruginosa, Achromobacter
xylosoxidans, and other pathogens from birth (46, 47). Failure to clear these pathogens
eventually leads to a positive feedback loop of neutrophil recruitment, degranulation, and
ineffective clearance. This can be observed in the bronchoalveolar lavage fluid (BALF),
where there is a large percentage of neutrophils recovered from these patients, as well as
increasing concentrations of the chemokine IL-8, correlating with bacterial infection (48).
Progressive bronchiectasis as a result of this inflammatory cycle, and mucus plugging from
the hyper-viscous submucosal gland secretions, significantly hampers lung function, as can
be observed through FEV1PRED measurements (43, 49). This lung disease is the leading
cause of morbidity and mortality in CF patient populations (42, 43, 47, 50, 51).
Often, bacteria in CF airways will undergo genetic changes in order to survive the
harsh inflammatory environment. Some of the more pathogenic bacterial strategies involve
the development of mucoid phenotypes in P. aeruginosa species, and the formation of
biofilm production in P. aeruginosa and many other CF-derived species (52, 53). Antibiotic
treatment strategies will select for mutants with high intrinsic antibiotic resistance, and as
such, antibiotic resistance will rapidly spread throughout the patient (54). As expected,
antibiotic resistance rates for CF patients are high, with 15% of patients colonized with
multi-drug resistant P. aeruginosa, although rates have been reported as high as 30% of P.
aeruginosa infected patients; drug-resistant S. aureus is observed in ~25% of patients (54–
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56). As a result, some antibiotics have become completely ineffective for CF patient
therapy, as it was observed in one study that over 70% of P. aeruginosa isolates were
resistant to amikacin, gentamicin, and fosfomycin, while over 90% of methicillin-resistant
S. aureus (MRSA) isolates were resistant to both clindamycin and erythromycin (57).
Eventually, physicians and patients are burdened with severely limited antibiotic options,
and the chronic lung infections caused by the multi-drug resistant bacteria result in hypoxia,
respiratory failure, and death (43).
While the understanding of CF pathophysiology has been well documented through
the use of various in vitro cell culture models and in vivo animal models that accurately
model the human course of disease, the development of multi-drug resistant bacterial lung
infections remains the most challenging clinical problem to manage. However, the ability
to isolate and culture multi-drug resistant bacteria allows for multiple permutations of in
vitro testing, including investigating the bactericidal activity of novel antimicrobial
agents against these clinically-isolated pathogens.
1.2.2 Ventilator-associated pneumonia
Ventilator-associated pneumonia (VAP) is the development of lower respiratory
tract infection >48 h after the initiation of treatment, and is one of the most common
hospital-acquired infections (58). Similar to the complex pathology associated with CF and
the development of CF-lung disease, the development of VAP is equally complex. The
development of VAP has been attributed to multiple different factors, such as damage
caused by the insertion of the tube leading to a breached epithelial defense layer, ineffective
host defense systems, and the patients’ impaired ability to swallow respiratory secretions,
all resulting in spontaneous airway colonization (59). Consistent with this variable disease
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etiology, the reported percentages of patients that develop VAP also vary widely, with
reports anywhere between 5-72% of patients receiving mechanical ventilation (60, 61). The
mortality rates for VAP patients is equally variable, with reports anywhere between 2076%, depending on the study (60, 62). Bacterial species commonly associated with these
infections include S. aureus, P. aeruginosa, Klebsiella pneumonia, and Acinetobacter
baumii (63).
Regardless of incidence rates, the pathology of VAP is similar to communityacquired pneumonia, with the major complication of an endotracheal tube. To complicate
the treatment of this pneumonia infection, the endotracheal tube acts as a reservoir for
bacteria, preventing the ability of the host defense system to completely clear the infection
(59). In addition, bacteria grown in this environment often form a biofilm, which makes
treatment of the infection even more difficult, as the biofilm acts as a shield to protect the
bacteria from host defense systems and antibiotic penetration (64).
Similar to CF patients, the prolonged bacterial colonization leads to rampant
pulmonary inflammation, eventually resulting in respiratory failure and death. Although
BALF collected from these patients is typically used to perform bacterial culture analysis,
analysis of this fluid presents with high rates of neutrophil influx and cytokine production
(58, 60, 61, 64, 65). Antibiotics are administered to manage these infections, but prevalence
of antibiotic resistant bacteria is anywhere between 42-69% (63, 66–69). Left untreated,
oxygenation becomes severely reduced and patients can develop acute respiratory distress
syndrome, eventually leading to multi-organ failure and death (60).
Despite the high incidence of multi-drug resistant infections associated with VAP,
the overall injury is severely understudied. However, there are multiple animal models
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useful for investigation, and useful physiologic measurements to investigate, such as
bacterial clearance, as well as oxygenation and inflammatory responses. These animal
models allow for a controlled environment in order to investigate VAP infections (70).
Using these models, it is possible to investigate the therapeutic potential of
antimicrobial/immunomodulatory agents that directly affect three clinically relevant
outcomes – oxygenation, bacterial clearance, and inflammation.

1.3 Antimicrobial Resistance and the need for novel therapeutics
As mentioned previously, the typical treatment for prolonged bacterial infection of
the airways is the administration of antibiotics. However, improper antibiotic usage, or
prolonged exposure to antibiotics without effective clearance of the bacteria, such as the
situation observed in cystic fibrosis patients, can lead to the development of drug-resistance
(71).
Increasing rates of multi-drug antibiotic resistance are quickly becoming a concern
in clinical settings, which limits the therapeutic options available to both patients and
physicians (6, 72–74). Antimicrobial resistance is one of the largest global threats currently
being faced, which has been caused by 1) the natural selection of drug-resistant bacterial
strains due to improper antibiotic use, as well as 2) poor stewardship of conventional
antibiotics and improper administration (75). In addition to intrinsic resistance strategies
found within the bacteria naturally, spontaneous mutations and horizontal gene transfer can
cause rapid dissemination of drug resistance, making the antibiotics ineffective against the
once-susceptible bacterial strains (52, 76). The increasing incidence of drug-resistant P.
aeruginosa, MRSA, and a variety of other bacterial species, is threatening treatment
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regimens of pneumonia patients, as therapeutic strategies become limited by the decreasing
number of effective antibiotics (4). In case of CF and VAP, the situation is more dire, with
drug-resistant bacteria being responsible for infection in between 9.2 – 26% and 42 - 69%
of cases, respectively (63, 66–69, 77).
The rising prevalence of antimicrobial resistance requires investment into the
development of new antibiotics. However, with fewer pharmaceutical companies investing
in the discovery of new therapeutics, there is a reduced number of new therapeutics
currently in development (75, 78). Consequently, a number of research groups have begun
to investigate the potential of antimicrobial peptides (AMPs) as potential sources of new
therapeutics (79–86).

1.4 Antimicrobial peptides
Antimicrobial peptides are a diverse group of endogenous peptides produced as part
of the innate immune system. They have been identified in almost every plant and animal
species investigated. A full list of the 2600+ peptides can be found here
(http://aps.unmc.edu/AP) (87). These peptides can be subdivided into different groups,
based on their tertiary structures, amino acid composition, or the ability to form disulphide
bonds through specific cysteine residues (87).
The two largest families within the antimicrobial peptide class are cathelicidins and
defensins. For the purpose of this literature review, we will focus solely on the role of
cathelicidins, and their potential for the treatment of multi-drug resistant bacterial
infections.
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1.4.1 Cathelicidins: mechanisms of action and therapeutic potential
Cathelicidins are a diverse family of peptides found in multiple species, including
(but not limited to) humans (88), rats (89), mice (90), and chickens (91). They are grouped
together based on a common pro-domain, known as a “cathelin” domain (named due to its
homology to the cathepsin-L-inhibitor), that is roughly 100 amino acids long (92, 93). The
full-length, unprocessed peptides contain a short signalling domain on the N-terminus, the
conserved cathelin domain, and the active cathelicidin peptide at the C terminus (94). The
N-terminal signal domain is responsible for directing the cathelicidin into storage granules,
at which point it is proteolytically removed (95–98). Once the secretory granules are
released, or fused with phagosomes, the active C-terminus is cleaved from the cathelin
portion by elastase (or proteinase 3, specifically for LL-37), releasing the active
antimicrobial peptide (96–104). Cathelicidins were first identified in leukocytes and
myeloid cells, but have since been identified in almost all epithelial and immune cells,
adding evidence for their important role in innate immunity (94, 105–111). Recently,
cathelicidin expression levels in circulating immune cells was investigated, which showed
highest levels of cathelicidin expression in neutrophils, followed by monocytes, and then
lymphocytes (112). Their expression and release can be both constitutive or upon
stimulation, either through activation by microbial products such as lipopolysaccharide
(LPS), or through stimulation by inflammatory cytokines, such as IL-1α (110, 113, 114).
In humans and primates, induction of cathelicidin production is regulated by vitamin D
receptor activation, not direct NF-κB regulation (115). Instead, toll-like receptor activation
induces cathelicidin production indirectly, via upregulation of the vitamin D receptor (116).
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1.4.2 Antibacterial activity
Initial interest in these peptides was due to their bactericidal properties (117).
Despite being phylogenically ancient, these peptides have maintained potent antimicrobial
activity with very few species of bacteria presenting with intrinsic resistance towards them.
The efficacy of these evolutionarily old peptides is due in part to the multiple mechanisms
of bactericidal activity (100, 118).
Upon their release from the secretory granules, the positively charged cathelicidins
interact with the negatively charged phospholipids found on the bacterial plasma
membrane, as well as components of the outer membrane, including lipoteichoic acid
(LTA) or LPS (119). These electrostatic interactions account for the selection of bacterial
cell membranes over the neutrally charged eukaryotic membranes (79). After the
interaction with the cell membrane, cathelicidins have been shown to function through two
methods (Figure 1.1). The first is solely through the cell membrane interactions, where the
peptides will permeabilize bacterial membranes through either carpet-, barrel stave-, or
toroidal pore-models, depending on the peptide in question (which varies due to each
cathelicidin’s structure, shape, and amino acid composition) leading to loss of membrane
integrity and bacterial death (100, 120–122). While it is possible for bacteria to undergo
major membrane neutralization to prevent cathelicidin binding, these changes often lead to
an evolutionary disadvantage once the selective pressure is removed. Additionally,
bacterial membrane neutralization appears to be limited, and the membrane changes are not
enough to completely prevent cathelicidin activity (123, 124).
In the second method, after binding and insertion into the bacterial membrane, the
peptide will move into the cell and interact with negatively charged molecules within
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(including DNA and RNA, amoung others) to prevent transcription, translation, and other
necessary bacterial survival activities (125). These multiple mechanisms of action make
rapid development of resistance very difficult for bacteria, and explains why these
phylogenetically ancient peptides still remain effective antimicrobials (124).
In multiple studies, cathelicidins have repeatedly been shown to effectively kill
Gram-positive, Gram-negative bacteria (108, 126), mycobacteria (104), as well as fungi
(127), and to neutralize membrane-enveloped viruses (128, 129), all of which are the
sources of clinically relevant infections in the airways. However, while their bactericidal
role has been well established in vitro, there are concerns about the activity of these peptides
within physiologically relevant settings. Travis et al. showed that, while all cathelicidins
investigated had potent bactericidal activity in the absence of salt, only two peptides
(SMAP-29 from sheep and CAP-18 from rabbits) showed similar bactericidal activity at
“high” salt concentrations (100mM NaCl) (130), which is still lower than physiologically
relevant conditions found within the lung (131). Other peptides, however, have been shown
to have salt-insensitive activity, such as CATH-2 (101, 132). However, various
modifications can affect bactericidal activity in these high salt conditions, as Veldhuizen et
al. demonstrated that shortening of cathelicidins, particularly through truncations to the Cterminal of the peptide, tends to lead to increased salt sensitivity with respect to
antimicrobial activity. They postulated that α-helix stability was one of the factors behind
the disparity in activity (133).
Regardless of the controversy surrounding their direct bactericidal role in vivo,
cathelicidins have been repeatedly shown to have direct anti-infective functions in
clinically relevant models of infection. They were first identified as key members of
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immunity in mouse models of Group A S. pyogenes skin infection, where loss of mCRAMP
expression via knockout led to reduced clearance of the bacteria and an increase in the
necrotic tissue area at the site of infection (134). This was one of the earliest studies to
provide direct evidence of cathelicidin function in vivo, which initiated the investigation of
these peptides in other disease models, including respiratory infections.
In CF, despite the failed bacterial clearance by the immune system, there are
significantly elevated levels of LL-37 within the sputum, which correlates with disease
severity (135). However, sputum samples that were treated with lipopolysaccharidebinding protein (LBP) and DNase in vitro were able to reduce bacterial load, presumably
by releasing the AMPs within the sputum from LPS and DNA/F-actin that may have been
binding to and masking the peptide’s direct bactericidal functions (136, 137). Loss of
endogenous cathelicidin expression in vivo has been shown to significantly reduce bacterial
clearance in infection models using K. pneumoniae and P. aeruginosa, again demonstrating
the important role of cathelicidins in the innate immune response towards bacterial
infections (138).
Despite the vast amount of research investigating the potential of cathelicidin
peptides as exogenous therapies, administration of exogenous cathelicidins and
cathelicidin-derivatives to directly treat bacterial lung infections in vivo have shown much
more modest results to date. A recent study by Mardirossian et al showed that, despite
efficacy in vitro and peptide tolerability in naïve animals, intratracheal instillation of
BMAP-27 and its peptide derivatives was unable to significantly reduce P. aeruginosa
bacterial load 24 hours after treatment (139). Using a similar model, Beaumont et al showed
that intratracheal administration of LL-37 after P. aeruginosa infection aids in the bacterial
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clearance, but via augmentation of the endogenous host defense system, not through direct
bactericidal activity (140).
Taken together, these studies provide evidence of the disparity in cathelicidin
activity between individual peptides with respect to direct bactericidal activity. The lack of
translational activity between in vitro studies and actual effects observed after in vivo
administration highlight the need for thorough investigation of various cathelicidins in
order to identify an optimal peptide which maintains salt-insensitive, in vivo bactericidal
activity, in order for further development of a clinical therapeutic agent.

19

Figure 1.1. a) A cartoon ribbon model of two α-helix structured cathelicidin peptides;
CATH-2 (blue), and LL-37 (red). b) Cathelicidins have been found to be endogenously
released by both macrophages (light blue), neutrophils (purple), and epithelial cells (not
shown) after induction of inflammatory signalling, at which point the peptide is now free
to interact directly with the bacterial membrane to begin bactericidal activities. The three
proposed mechanisms of bactericidal activity via pore formation are c) barrel-stave model,
where the neutrally-charged portion of the cathelicidin interacts with the lipid tail groups
of the bacterial cell membrane, eventually forming a pore; d) the toroidal pore model, in
which the positively-charged portions of the peptide interact with the negatively-charged
phospholipid head groups by inserting into the bacterial membrane, forcing the membrane
to fold inwards as well; e) carpet model, in which the peptides orient in parallel to the
bacterial membrane, and upon reaching a “critical” concentration, form micelle-like
structures and lyse the cell membrane. f) Mechanisms of intracellular activity, which
include inhibition of DNA, RNA, and protein synthesis.
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1.4.3 Cathelicidin immunomodulatory activity
As a result of the unclear nature of cathelicidins’ bactericidal activity in vivo, some
research groups have begun testing cathelicidin immunomodulatory activity (83, 141–143).
It has been well documented, both in vitro and in vivo, that cathelicidins are able to
modulate inflammatory signalling, by either eliciting a pro-inflammatory or antiinflammatory signal, which appears to be dependent upon microbial stimulation and
microbial by-products initiating the signal (140, 144, 145).
The presence of the human cathelicidin LL-37 has been shown to skew
differentiating monocytes towards M1 (pro-inflammatory) macrophages (146). However,
LL-37 has been shown to be able to reduce pro-inflammatory cytokine production from
these M1 macrophages if co-administered with LPS or LTA at physiologically relevant
levels, without affecting macrophage phagocytic activities (82). There is evidence that LL37 appears to inhibit cytokine expression of stimuli activating the toll-like receptors TLR
2 and TLR 4 (LTA and LPS, respectively) (144). However, this anti-inflammatory activity
appears to be very specific, as cytokine production after stimulation by of TLR2/1 via the
synthetic lipopeptide PAM3, or TLR2/6 via ZymA is not affected by administration of LL37 (82, 146).
Asides from LL-37, other cathelicidins have been shown to have similar activity
across several distinct species. Murine CRAMP has been shown to act similarly to LL-37,
inducing macrophage polarization and reducing cytokine production upon microbial
stimulation by LPS, LTA, as well as bacterial flagellin (a TLR 5 agonist) (147). Chicken
cathelicidins CATH-1, -2, and -3 have been shown to similarly block LPS-induced cytokine
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production from mouse macrophage cell lines, which importantly indicates cross-species
activity (101, 132, 148).
However, the anti-inflammatory properties of cathelicidins are not as straightforward as initially suspected. Both LL-37 and CATH-2 have been shown to be involved
in the association of DNA complexes that activate TLR 9 and increase inflammatory
signalling (149, 150). Similarly, mCRAMP-knockout (CAMP-/-) mice showed a reduced
ability to respond after CpG DNA injection through a reduction in inflammatory cytokine
production (TNF-α, IL-6), while it was shown at the same time that mCRAMP is
responsible for complexing with CpG DNA and TLR 9 in the endolysosome of murine
macrophages (151).
Adding to their immunomodulatory properties, many cathelicidins have also been
documented to act as chemoattractant agents. LL-37 has been shown to induce chemotaxis
in monocytes, neutrophils (152), eosinophils (153), and T-cells (154). Similar neutrophil
chemotactic activities have been found for additional peptides, such as mCRAMP, PR-39
(155), and chicken CATH-1 (156), while mononuclear cell recruitment appears to be less
universal. The chemotactic functions of these peptides appears to be regulated through the
formyl peptide receptor 2/formyl peptide receptor-like 1 (FPR2/FPRL1) (152). Similar
receptor interactions have been identified for other species, such as mCRAMP and the
murine homologue of FPR2 (157). For mast cell specific mobilization and activation, LL37 has been able to act through the MrgX2 receptor specific to mast cells (158). There is
also some evidence of LL-37 acting as a direct ligand for the CXCR2 chemokine receptor
found on neutrophils, where interaction induces calcium influx in a dose-dependent manner
(159).
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Independent of their direct chemotactic activity, cathelicidins are also able to
upregulate the production of chemokines from other cell types. Macrophages stimulated
with LL-37 produced significantly higher levels of MCP-1, a key chemokine for the
recruitment of monocytes, natural-killer cells, and T-cells, however LL-37 incubation with
LPS inhibited the release of MCP-1 from airway epithelia. Additionally, stimulation with
LL-37 alone produced IL-8, a neutrophil chemokine, in a dose dependent manner (160).
This IL-8 production appears to be through the interaction of these peptides with both the
P2X7 receptor and epidermal growth factor receptor, and has been shown to be produced
from epithelial cells, fibroblasts, and macrophages (161–163). LL-37 binding with GAPDH
from monocytes also induces the production of CXCL1, another neutrophil chemokine
(145).
Based on the studies of immunomodulatory activities described above, cathelicidins
have become attractive therapeutic targets as immune system adjuvants. Summation of the
data presented above suggests that cathelicidins have the ability to maintain a complex
inflammatory balance within an infection environment. This capability to balance the
immune system, ensuring a sufficient inflammatory response to eliminate invading
pathogens while preventing excessive host responses, suggests that cathelicidins are
extremely promising as therapeutics for many chronic lung diseases, and especially CF
lung disease where excessive pro-inflammatory activation often leads to collateral tissue
damage and remodelling. The use of a cathelicidin peptide that possesses antibacterial
activity in vivo, while being able to modulate inflammatory responses, would be an ideal
therapeutic for this type of disease.
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1.4.4 Chicken cathelicidin CATH-2
CATH-2 is one of four cathelicidins found in chickens (91). Produced almost
exclusively by heterophils (chicken homologue of human neutrophils), the active CATH-2
peptide is cleaved from its pro-piece by serine proteases and released upon immune system
stimulation, such as LPS activation (164). Once released, the peptide can exert its potent
broad-spectrum microbicidal activity (127, 132). CATH-2 shows antimicrobial activity
against a wide variety of both chicken and human pathogens, generated minimum
inhibitory concentration (MIC) values between 0.6-5.3 µM. Unlike other cathelicidin
peptides, this antimicrobial activity appears to be unaffected by increasing salt
concentrations (101, 132, 165). CATH-2 appears to kill through multiple mechanisms of
action, depending on peptide concentration, including direct membrane permeabilization,
as well as interacting with intracellular components, although the exact target is unknown
(166).
In addition to this salt-insensitive broad-spectrum activity, CATH-2 has also been
shown to have strong immunomodulatory activity. It has been shown to directly bind to
multiple immunostimulatory products, such as LPS (132, 166, 167). Interactions of CATH2 with LPS, as well as the gram-positive endotoxin LTA, are able to significantly reduce
TNF-α production from macrophages in vitro, while interactions with CpG DNA increases
TNF-α production, consistent with observations from other cathelicidin peptides (151,
167).
In vitro, CATH-2 has demonstrated the unique ability to kill a broad-spectrum of
human pathogens, maintains bactericidal activity within physiologically relevant salt
concentrations, and is able to modulate inflammatory responses in vitro across multiple
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different stimulatory molecules, in both chickens, as well as mouse cell lines. Based on
both its bactericidal and immunomodulatory effects, CATH-2 is a highly promising
cathelicidin of interest for further investigation. However, the use of CATH-2 in in vivo
models, and its bactericidal activity against multi-drug resistant human pathogens, is yet
unknown.

1.5 Cathelicidins in clinical trials
Due to their multiple mechanisms of bactericidal activity, cathelicidins are ideal
peptides for next generation antibiotics due to their low propensity for the development of
bacterial resistance. Despite the bacterial development of protease secretion and
membrane/exotoxin post-translational modifications as possible resistance mechanisms,
the fact that these peptides retain broad-spectrum activity against a variety of human
pathogens reinforces their clinical potential in future therapies (124).
According to ClinicalTrials.gov, there are currently approximately 80 trials
involving cathelicidins, as well as other antimicrobial peptides, either through direct
administration of exogenous antimicrobial peptides, through treatments aimed to increase
endogenous cathelicidin pool sizes within patients (through the administration of butyrate,
vitamin D, or their alternative forms), or through treatments aimed at the inhibition of
cathelicidin production for diseases of peptide over expression. In addition, there is a large
field of research involving pre-clinical studies investigating multiple cathelicidin peptides
in many infection and disease states (141).
However, despite the therapeutic promise of cathelicidin peptides, very few have
been developed through all stages of clinical trials. Obstacles to development often involve
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either toxicity towards eukaryotic cells, which can be observed at high doses (101), or the
poor stability of cathelicidin peptides to endogenous proteases found in the gastrointestinal
tract, serum, and even bronchoalveolar lavage fluid (83, 139). Therefore, optimal
cathelicidin therapy for pulmonary infections would require a) a peptide that is functional
in the pulmonary, high salt, environment, b) a method to protect the peptide from
degradation, limited toxicity, and c) a method to deliver it directly to the injured location.

1.6 Delivery of therapeutics to the airways
During

treatment

of

lower

respiratory

tract

infections,

adequate

antibiotic/antimicrobial site concentrations are imperative for the clearance of infection.
This is made difficult by the unique branching structure of the lung (168). Despite this, the
delivery of antibiotics directly to the site of infection within the lung, which is currently
limited to aerosolized administration, has numerous benefits over current systemic
administration routes, including increased local concentrations of antibiotics, and enhanced
microbial clearance. Furthermore, there is a reduced risk of systemic toxicity which is
common in numerous conventional antibiotics (29, 169–171). However, aerosolized
administration of antibiotics is typically found to accumulate in the central airways, with
large volumes of antibiotics required to reach adequate concentrations at the distal sites of
infection (30, 172, 173). Therefore, to optimize delivery of therapeutics to the lungs, other
drug delivery vehicles must be identified.
1.6.1 Exogenous pulmonary surfactant as a vehicle for therapeutic delivery
In order to overcome these delivery issues, many groups have investigated the
potential of pulmonary surfactant as a delivery vehicle (29, 169, 170, 174–177). Pulmonary
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surfactant is a lipoprotein mixture, endogenously produced by type II alveolar cells within
the lung, composed of approximately 80-85% phospholipids, 5-10% neutral lipids, and 510% surfactant specific proteins (9, 13). Exogenous clinical surfactants, derived from
animals including bovine and porcine sources, have been used over the past 35 years as a
treatment for neonatal respiratory distress syndrome, which is characterized in premature
infants as a lack of sufficient endogenous surfactant (19, 178, 179). Surfactant acts by
adsorbing and spreading at the air-liquid interface within the alveoli and acts to reduce
surface tension, thereby improving lung compliance and preventing alveolar collapse upon
exhalation (14).
The spreading capabilities of surfactant has been investigated as a potential
mechanism of distributing therapeutics to distal airways (29). The benefits of surfactant
spreading were first demonstrated by Kharasch et al., who showed that surfactant
administration was superior to aqueous solution administration with regards to lung tissue
distribution (30). They demonstrated that surfactant was able to disperse more uniformly
throughout the lungs, in comparison to saline solution, which tended to localize to the
central lung regions (30). Surfactant distribution rates are also far superior to current
practices involving aerosolized administration, which only achieves ~10% deposition in
small airways (180, 181).
Based on the promise of these initial distribution studies, several groups began
investigating the potential of utilizing surfactant as a respiratory vehicle, with the purpose
of increasing concentrations of therapeutics at the infection site and reducing toxicity risks
of systemically administered antibiotics (29, 30, 170, 176). Van’t Veen et al. were able to
show that the combination of surfactant with the antibiotic tobramycin was able to
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significantly improve survival in mice infected with K. pneumoniae compared to animals
receiving surfactant alone, or tobramycin alone (176). The same group was then able to
show that the in vivo administration of a surfactant preparation with cyclosporine A
suspended in ethanol had no impact on surfactant function (177), and were able to reduce
inflammation and acid sphingomyelinase activity after “fortification” of surfactant with a
NF-κB inhibitor (182).
As mentioned previously, pulmonary surfactant has been used as a clinical therapy
from 1980 for the treatment of neonatal respiratory distress syndrome (25). While the use
of surfactant for the treatment of adult respiratory distress syndrome failed to show
significant clinical improvement, it has repeatedly been demonstrated to be a safe
therapeutic (183). However, more recent studies have begun investigating the potential of
surfactant as a mucokinetic agent, which would act to improve clearance of mucus plugging
(184). Studies by Al-Saiedy et al. demonstrated that the addition of the exogenous
surfactant BLES to an in vitro mucus plug system was able to improve mucus “velocity”
over the course of ventilation (185).
Along with its potential as a respiratory vehicle, the multifunctionality of a
combined surfactant/antimicrobial peptide compound to distribute therapeutics throughout
the airways, reduce mucus plugging, and eliminate multi-drug resistant bacteria would be
of major therapeutic benefit as a treatment for many different respiratory diseases,
including cystic fibrosis and ventilator-associated pneumonia. However, as demonstrated
by van’t Veen et al., this combination must be able to maintain the innate functions of each
of its parts, as some antibiotics have demonstrated a loss of activity after instillation with
surfactant, and surfactant inactivation would compromise lung function (175).
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1.7 Summary, objectives, and hypothesis
Over the course of respiration, the lung is constantly bombarded with pathogenic
bacteria. In some cases, these bacteria are able to circumvent the natural host defense
systems and develop into an airway infection. Left untreated, these infections can lead to
severe tissue damage in the lungs, resulting in inefficient gas exchange, poor oxygenation,
respiratory failure, and eventually death. Normally, treatment of these infections involves
a simple course of antibiotics, resulting in clearance of the pathogen. However, ineffective
antibiotic stewardship combined with a lack of pharmaceutical investment has cumulated
into a global healthcare “perfect storm” with the increasing emergence of antibiotic
resistant bacteria. There is a dire need for the development of novel therapeutics for
the treatment of antibiotic resistant bacterial infections.
To develop these new therapeutics, we have investigated the potential of
cathelicidin

peptides.

Their

direct

antimicrobial

activity,

coupled

with

their

immunomodulatory functions, are theoretically ideal for the treatment of infection, as they
present the ability to directly kill colonized bacteria while downregulating the inflammatory
response associated with bacterial death. In addition to cathelicidins, we have investigated
an exogenous pulmonary surfactant, BLES, as a vehicle for these cathelicidin peptides, in
order to improve therapeutic administration into the peripheral airways of the lung.
However, interaction between cathelicidin peptides and exogenous pulmonary
surfactant is currently unknown. In Chapter 2, we investigated the proof-of-principle of
a cathelicidin/surfactant compound, and select an optimal cathelicidin for therapeutic
use. This investigation was performed by assessing the biophysical and antimicrobial
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activities of multiple cathelicidin peptides in combination with exogenous surfactant in
order to select an ideal peptide/surfactant combination for future therapeutic study. Once
identified, we tested the safety of this therapeutic after intratracheal administration in naïve
animals.
After identifying the optimal cathelicidin/surfactant combination, and performing
safety studies, Chapter 3 investigated the immunomodulatory activity of the selected
cathelicidin, CATH-2, using administration of killed P. aeruginosa. Bacteria were
killed via three separate mechanisms, and intratracheally instilled into mouse lungs in order
to study the inflammatory response elicited. The ability of CATH-2 to kill bacteria in an
immunogenically “silent” manner, as well as the ability of CATH-2 to down-regulate the
inflammatory response of other killed-bacteria were investigated.
Following the investigation of CATH-2’s immunomodulatory activity, Chapter 4
focused on the bactericidal and immunomodulatory properties of BLES+CATH-2
against multi-drug resistant clinical isolates obtained from CF patients. Similar to
previous methodology, we investigated the in vitro bactericidal activity of BLES+CATH2, and investigated the immunomodulatory activity of BLES+CATH-2 upon instillation in
vivo with heat-killed bacteria.
Finally, in Chapter 5 we investigated the bactericidal and immunomodulatory
activity of BLES+CATH-2 in two distinct models of pneumonia. To test this, two
models - a mouse model of bacterial pneumonia, and a rat model of ventilator-associated
pneumonia - were used to assess the bactericidal activity of BLES+CATH-2 treatment in
vivo in clinically relevant models of respiratory infections.
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The overall objective of this thesis was to develop an antibiotic-alternative, novel
therapeutic for the treatment of multi-drug resistant respiratory infections. The overall
hypothesis is that the administration of a cathelicidin/surfactant compound will improve
clinically relevant outcomes in the treatment of bacterial pneumonia.
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2.1 Introduction
The emergence of highly resistant strains of bacteria currently represents a
significant public health issue for patients due to the pervasive use of antibiotics on a global
scale. Patients with acute or chronic pulmonary infections where antibiotic use is
widespread, such as in case with cystic fibrosis and ventilator-associated pneumonia,
antimicrobial resistance is particularly problematic and is a strong predictor of poor
outcomes (1). Furthermore, the distinct structure of the lung, combined with the potential
of inaccessible areas due to collapse and edema arising from infections, significantly
impairs effective antimicrobial drug delivery in this organ. New, innovative therapeutic
approaches to combat lung infections are desperately needed.
Antimicrobial peptides (AMPs) form part of the innate immune system and are
evolutionarily conserved across a wide variety of organisms including humans (2). One
class of antimicrobial peptides, cathelicidins, possess antimicrobial function through a
variety of mechanisms including direct interaction with bacterial cell membranes and
interference of intracellular bacterial targets (2). The net positive charge of these peptides
ensures they are more likely to interact with the negative cell walls of bacteria than the
neutral cellular membranes of eukaryotic cells. Importantly, it has been demonstrated that
they remain functional against microbes with antibiotic resistance, and considering their
mechanism of action, it is less likely that resistance will develop due to the changes in
membrane structure that would be required for effective resistance (2). It has been shown
in vitro that AMPs can induce transient resistance, but there is no evidence that this occurs
in vivo (3). Based on these properties, antimicrobial peptides have received a lot of attention
as alternatives to antibiotics, particularly for topical therapies (4). Utilization for pulmonary
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infections has been investigated but is complicated by delivery issues and to date has not
been successful in clinical trials (5–7).
To address the pulmonary delivery issue, exogenous surfactant has been proposed
as carrier for a variety of biological agents (8). Exogenous surfactant is derived from
endogenous pulmonary surfactant, a lipoprotein complex naturally produced by type II
alveolar cells, that is made up of approximately 80-85% phospholipids, 5-10% neutral
lipids (including cholesterol), and 10% proteins (9). The main function of surfactant is to
reduce surface tension at the air-liquid interface of the alveoli. To accomplish this goal,
surfactant adsorbs and spreads rapidly to form a surface film consisting or lipid-condensed
and lipid-expanded regions at the air-liquid interface which upon lateral compression forms
a stable multilayer structure capable of reducing surface tension values to near 0 mN/m (10,
11). Through its ability to spread throughout the lung and open up collapsed lung areas,
exogenous surfactant therapy has been shown to reduce mortality of premature infant
afflicted with neonatal respiratory distress syndrome (12).
The general characteristics of surfactant and positive findings of exogenous
surfactant therapy led to a number of laboratory studies to investigate the possibility of
exogenous surfactant as a pulmonary delivery vehicle for other drugs (13–17). The
rationale for this approach is that the spreading properties of surfactant would improve
therapeutic distribution throughout the lung, while opening of collapsed lung regions to
improve drug availability directly at the site of an infection (8). Imperative for this approach
is that the drug of choice does not impact surfactant's ability to spread throughout the lung
and reduce surface tension, and, vice versa, that surfactant does not interfere with the
therapeutic efficacy of the drug.
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Based on this information our objective was to evaluate the spreading, biophysical
capabilities, and bactericidal function of four cathelicidin peptides, CATH-1, CATH-2,
mCRAMP, and LL-37, combined with a clinical exogenous surfactant, bovine lipid-extract
surfactant (BLES). Maintenance of respective surfactant and cathelicidin functions when
the two compounds are combined would provide a first proof-of-principle toward the
hypothesis that a combination treatment of cathelicidins with an exogenous surfactant
vehicle would be effective in treating antibiotic resistant lung infections.
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2.2 Materials and Methods
Surfactant/Peptide Compounds
BLES (BLES Biochemicals, London, ON, Canada) is a commercially available
clinical preparation, stored in 100 mM sodium chloride and 1.5 mM calcium chloride with
a phospholipid concentration of 27 mg/ml. BLES contains natural phospholipids found in
bovine surfactant, along with surfactant-specific proteins SP-B and SP-C and a small
percentage of cholesterol.
Antimicrobial peptides were synthesized using Fmoc solid-phase synthesis as
described previously (18). All peptides were purified to a minimum purity of 95% by
reverse phase high-performance liquid chromatography prior to biological testing. The
sequences of the peptides used in this study are shown in Table 2.1. Four AMPs were
tested in this experiment: chicken cathelicidin-1 and 2 (CATH-1, CATH-2), mouse
cathelicidin CRAMP, and human cathelicidin LL-37. All peptides were suspended in
non-buffered sterile saline. BLES and peptide were mixed to concentrations of 10 mg/ml
BLES, and 10/40/100/200 µM for the peptides.
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Peptide
CATH-1
CATH-2
mCRAMP
LL-37

Amino Acid Sequence

Net
Charge
RVKRVWPLVIRTVIAGYNLYRAIKKK
+8
RFGRFLRKIRRFRPKVTITIQGSARF
+9
GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ
+6
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES +6

Table 2.1 Amino acid sequence and charge of cathelicidins investigated.
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Spreading
Adsorption of BLES and the various peptides were measured using the Wilhelmy
probe and FilmWare 2.51 software of the Langmuir balance. A petri dish with a diameter
of 100 mm, and surface area of 78.54 cm2 was used. It was filled with 25 ml of 10% sucrose,
with a 15 ml layer of ddH2O layered on top. The probe of the Langmuir balance was placed
on the surface of the ddH2O sub-phase, and 50 µl of each peptide-surfactant sample was
pipetted into the water phase. The surface tension was recorded over the subsequent 600
seconds.

Minimal surface tension over multiple compression-expansion cycles
To investigate the minimum achievable surface tension over ten compressionexpansion cycles, a constrained sessile drop surfactometer (CDS) (BioSurface Instruments,
HI) was used (19–21). A ten microliter drop of sample was placed upon the drop pedestal,
and using an external stepper motor, the drop was cyclically compressed-expanded for 10
cycles at a rate of 5 seconds/cycle, and a compression ratio of approximately 27%. Images
of the droplet were recorded at a rate of one image per second, and were analyzed. The
image with the lowest surface tension throughout each cycle was determined to be the
minimum surface tension (MST) for that cycle. Minimum surface tensions for all 10 cycles
were measured.

AFM imaging of surface films
In order to examine the effect of peptides on the surfactant surface films, LangmuirBlodgett films were prepared using a Kibron™ Trough SE (Helsinki, Finland). Briefly,
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films were spread by depositing droplets of surfactant samples uniformly throughout the
air–water interface. Deposits were taken at surface pressure of 30 mN/m on freshly-cleaved
mica. Topographical atomic force microscope (AFM) images were obtained using a
Nanoscope III scanning force multimode microscope (Digital Instruments, Santa Barbara,
CA). Samples were scanned with a J-type scanner using contact mode in air. A silicon
nitride cantilever with a spring constant of 0.12 N/m was used. Image analysis was
performed using the Nanoscope III software (version 5.12r3). All AFM images were
subjected to quantitative analysis using ImageJ Software (National Institute of Health) to
determine the surface area of condensed domains. At least 9 AFM images were used for
each sample and the results are shown as averages and standard error.

Antimicrobial assays
An overnight culture of either Methicillin-resistant Staphylococcus aureus WKZ-2,
or Pseudomonas aeruginosa VW178 (isolated from a cystic fibrosis patient) were diluted
1/1000 in tryptic soy broth (TSB) and left to incubate for three hours at 37°C in order to
reach exponential growth phase. The optical density was measured, and bacteria were
further diluted in PBS to reach an initial concentration of approximately 2x106 CFU/ml.
From there, 25 µl of peptides at various concentrations, with or without BLES, were added
to polypropylene coated round-bottom 96 well plates, along with 25 µl of bacteria, and
incubated at 37°C for three hours with no shaking. Subsequently, 200 µl of minimal media
was added, and the colonies were serially diluted 10-1000-fold. After the serial dilution,
100 µl of each dilution were plated on tryptic soy agar (TSA) plates and left to incubate
overnight at 37°C. Following overnight incubation, the colonies on the plates were counted.
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Minimum bactericidal concentrations (MBC) were defined for these experiments as the
concentration of surfactant/peptide compound at which less than 10 colonies were counted
at the highest dilution, corresponding to less than 100 CFU/ml.

In vivo analysis of safety and tolerability of BLES+CATH-2 treatment
Male C57Bl/6 mice (Charles River, Sherbrooke, Qc, Canada), weighing 22-30 g,
were used for this experiment. All animal procedures were approved by the Animal Use
Subcommittee at the University of Western Ontario, and followed the approved guidelines
described by the Canadian Council of Animal Care. Mice were anesthetized by
intraperitoneal injection of a ketamine (100 - 125 mg/kg body weight) and
dexmedetomidine (0.5 mg/kg BW) mixture, and then intubated using a 20 G catheter, with
the aid of a fiber-optic stylet (BioLite intubation system for small rodents, BioTex, Inc.,
Houston, Texas, USA). Once intubated, the mice were instilled with 50 µl of one of five
treatments: a) air bolus, b) sterile saline, c) BLES (10 mg phospholipid/ml), d) CATH-2
(100 µM, suspended in sterile saline), or e) BLES+CATH-2 (10 mg phospholipid/ml, 100
µM peptide). Mice were extubated following successful instillation and were subsequently
injected with the reversal agent for dexmedetomidine, Antisedan, and allowed to breathe
spontaneously for the following four hours. After four hours, the mice were euthanized by
intraperitoneal (IP) injection of sodium pentobarbital (110 mg/kgBW) and dissection of the
descending aorta. The animals were placed on a FlexiVent© in order to measure
physiologic parameters, such as lung capacity, compliance, and airway resistance.
Following these measurements, whole lung lavage was collected by 3 x 1 ml aliquots of
sterile saline. The whole lung lavage was immediately centrifuged at 150 x g at 4°C, and
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the pellet was collected for cell analysis, while the supernatant was used to measure protein
and IL-6 content. Differential cell analysis of the cells obtained in the lavage was done as
previously described (22). Protein content within the lavage fluid was measured using a
Micro BCA protein assay kit (Pierce, Rockford, Ill., USA), according to manufacturer’s
instructions. IL-6 levels were measured using an enzyme-linked immunosorbent assay
(ELISA) kit (BD Biosciences, San Diego, Calif., USA), according to manufacturer’s
instructions.

Statistical Analysis
The effect of various cathelicidin peptides on BLES’ surface tension reducing
capabilities, and adsorptive properties, were calculated by one-way measure analysis of
variance (ANOVA) followed by a Dunnett post-hoc test using BLES as the control group.
Analysis of in vivo assays were performed by one-way ANOVA followed by Tukey posthoc test. Means are reported ± SEM and values were considered significantly different at a
probability value < 0.05.
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2.3 Results
Surface Tension after 600 seconds
Initial assessment involved an analysis of the ability of the surfactant plus peptides
to form a surface film on a clean air-water interface. This data reflects the “spreadability”
of the surfactant which, extrapolating to a clinical scenario, is an important indicator of the
ability of this material to distribute throughout the lung and reach the distal airways and
alveoli. Each sample was allowed to form a film for 600 seconds and surface tension
reached was recorded. As shown in Figure 2.1, there were no significant differences in the
end surface tensions between any of the surfactant/cathelicidin mixtures at 10 µM
concentrations and BLES (control). However, at a cathelicidin concentration of 40 µM, a
significant decrease in the surface tension at the end of 600 seconds of spreading was
observed for BLES+CATH-1 (p<0.01) and BLES+CATH-2 (p<0.05) mixtures compared
to

BLES

(control)

indicating

improved

spreading

characteristics.

All

four

surfactant/cathelicidin mixtures tested resulted in significantly lower surface tension at the
end of 600 seconds spreading at 100 µM concentrations compared to BLES controls.
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Figure 2.1. Adsorption assay of exogenous surfactant BLES in mixture with cathelicidin
peptides. a) CATH-1, b) CATH-2, c) mCRAMP, and d) LL-37 at concentrations of 0, 10,
40, and 100 µM. Values are mean surface tension ± SEM after 600s. (n=3) *p<0.05 vs.
BLES (Control), **p<0.01 vs. BLES (Control).
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Minimum surface tension over multiple compression cycles
In order to examine the surface tension reducing function of the peptide/surfactant
mixtures, the samples underwent ten cyclic compressions at a rate of five seconds/cycle via
the CDS, as a physiologically relevant model of multiple expansion-contraction cycles
during respiration. Minimum achievable surface tension (MST) values were recorded for
ten cycles, as a marker of surfactant activity which, in the in vivo situation, would reflect
the ability of this material to stabilize the alveoli and allow for ease of inflation. BLES
alone was able to reach MST values of ~2.5 mN/m consistently over all ten cycles. It was
observed that all concentrations of BLES+CATH-2 had a robust surface tension reducing
activity, consistently reaching MST values below 4 mN/m. BLES+CATH-2 only showed
significantly higher MST values at cycles 8, 9, and 10 at a concentration of 10 µM
compared to BLES (control). BLES+CATH-1 mixtures at 40 and 100 µM concentrations
showed significantly higher MST values compared to BLES (control) at cycles two through
ten (Figure 2.2a), increasing slightly from 4 mN/m to MST of roughly 5 mN/m at the end
of the ten compressions. BLES+mCRAMP mixtures had consistently higher MSTs of
approximately 4.5 mN/m over all cycles at 40 and 100 µM compared to BLES alone (Figure
2.2c). BLES+LL-37 mixtures had significantly increased MSTs between 4.5-5.5 mN/m
over all cycles versus BLES (control), but only significantly different at concentrations of
10 and 40 µM (Figure 2.2d). Minimum surface tensions of BLES+LL-37 mixtures at 100
µM were not statistically different from the BLES (control). Mixtures of BLES+CATH-2
were the only surfactant/cathelicidin mixture to show no significant difference versus
BLES (control) at 40 and 100 µM concentrations.
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Figure 2.2. Measurement of minimum surface tension during cyclic compressions of
exogenous surfactant BLES in mixture with cathelicidin peptides. a) CATH-1, b) CATH2, c) mCRAMP, and d) LL-37 at concentrations of 0 (open circle), 10 (triangle), 40
(diamond), and 100 µM (circle). Values are mean minimal achievable surface tension ±
SEM. (n=3-5) α = 10 µM <0.05 vs. BLES (Control), β = 40 µM < 0.05 vs. BLES (Control),
δ = 100 µM <0.05 vs. BLES (Control).
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Atomic force microscopy images
To assess the influence of peptides on surfactant film structure, AFM images were
analyzed focusing specifically on the formation of liquid condensed domains, as these
domains have been suggested to be important in surfactant function (11). Characteristic
AFM topographic images of BLES films in the absence and presence of 100 µM peptides
(CATH-2, CATH-1, LL-37 and mCRAMP) are shown in Figure 2.3. The brightness in
these images is proportional to the height. Phase separation, as indicated by the presence
of lighter, condensed domains, is evident in all samples at surface pressure of 30 mN/m
(Figure 2.3 a-e). Quantitative analysis of these images shows that addition of CATH-1 and
CATH-2 to BLES leads to a change in its lateral organization. More specifically, addition
of CATH-1 and CATH-2 to BLES leads to an increase in the number of condensed domains
and a decrease in the average surface area of the individual domains (Figure 2.4). Addition
of LL-37 and mCRAMP to BLES has no significant effect on average surface area of
condensed domains at surface pressure 30 mN/m (Figure 2.4).
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Figure 2.3

+LL37

Figure 2.3. Characteristic AFM topographic images showing the effect of peptide addition
on the lateral organization of BLES monolayers. The scan area is 20 x 20 µm2. All films
were deposited at a surface pressure of 30 mN/m. (a) BLES; (b) BLES + 100 µM CATH1; (c) BLES + 100 µM CATH-2; (d) BLES + 100 µM mCRAMP and (e) BLES + 100 µM
LL-37.
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Figure 2.4. Quantiﬁcation results showing the effect of peptide addition (CATH-1, CATH2, mCRAMP, and LL-37) on the size (i.e. surface area) of the condensed domains in BLES
monolayers at surface pressure 30 mN/m. These results were obtained from four unique
AFM topographic images of different samples. (n=2-24)
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Antimicrobial assays
In order to determine the bactericidal properties of the surfactant/cathelicidin
mixtures, bactericidal assays of each peptide were performed in both the presence and
absence of BLES. CATH-1, CATH-2, and LL-37 in PBS were found to have MBC values
of 5 µM, reducing CFU/ml values of MRSA by more than four log units (Figure 2.5a,b,d),
while mCRAMP reduced levels by three log units at 40 µM concentrations (Figure 2.5c).
In the presence of BLES (Figure 2.5), CATH-2 had a MBC of 200 µM, but had considerable
antimicrobial activity resulting in a two-log reduction of viability counts at 50 µM. CATH1 reduced CFU/ml levels by two log units at 200 µM, while mCRAMP and LL-37 mixtures
resulted in either a one log reduction, or no reduction at 200 µM concentrations in the
presence of BLES.
Similar results were seen against P. aeruginosa, where CATH-1, CATH-2, and LL37 peptides (in the absence of BLES) had MBC values from 5-10 µM (Figure 2.6), while
mCRAMP reduced bacterial viability by three log units at 40 µM (Figure 2.6c). In the
presence of BLES, CATH-2 again had a MBC of 200 µM, and a three-log reduction at 50
µM. CATH-1 reduced P. aeruginosa viability by three log units at 200 µM. mCRAMP and
LL-37 showed negligible bactericidal activity in BLES up to 200 µM concentrations.
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Figure 2.5
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Figure 2.5. Antimicrobial activities of cathelicidins against MRSA. a) CATH-1, b) CATH2, c) mCRAMP, and d) LL-37 in the absence (square, solid line) and presence (triangle,
dotted line) of 10 mg/ml BLES against Methicillin-resistant Staphylococcus aureus WKZ2 in PBS after 3h at 37°C. (n=3)
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Figure 2.6
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Figure 2.6. Antimicrobial assay of cathelicidin peptides against P. aeruginosa. a) CATH1, b) CATH-2, c) mCRAMP, and d) LL-37 in the absence (square, solid line) and presence
(triangle, dotted line) of 10 mg/ml BLES against Pseudomonas aeruginosa VW178 in PBS
after 3 h at 37°C. (n=3)
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In vivo analysis of BLES+CATH-2 treatment
The results of the experiment testing safety and tolerability are shown in Figure 2.7.
The experiment focused on CATH-2 and included two control groups (air and saline
instilled groups) and three experimental groups (CATH-2, BLES + CATH-2 and BLES
instilled groups). Analysis of lung physiology included lung compliance and airway
resistance (Figure 2.7a-b) which showed no significant difference among the groups. Mice
that were instilled with CATH-2 alone had significantly higher protein content within the
bronchoalveolar lavage fluid (BALF) versus animals in other treatment groups, and had
significantly increased IL-6 levels versus animals treated with BLES alone (Figure 2.7c-d).
BLES+CATH-2 treated animals showed no significant difference in protein or IL-6 levels
when compared with air, saline, or BLES controls. Cell count analyses found no significant
difference in total cell counts (Figure 2.7e) or neutrophil recruitment (Figure 2.7f) for any
treatment group.
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Figure 2.7
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Figure 2.7. From in vivo tolerance model, a) compliance of the respiratory system, and b)
airway resistance, as measured by FlexiVent; c) protein content, d) IL-6 content, e) total
immune cells, and f) total number of recruited neutrophils obtained from animal BALF
samples. (n=5-6) *p < 0.05.
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2.4 Discussion
The goal of the current study was to investigate the biophysical and antimicrobial
properties of four novel surfactant/cathelicidin mixtures and to determine whether
combining such elements together impacts native function. Four cathelicidin peptides were
tested in combination with an exogenous surfactant, BLES. The presence of all cathelicidin
peptides accelerated surface film formation of BLES as indicated by the spreading
capabilities of BLES plus peptides over 600 seconds. While all other cathelicidin peptides
decreased the ability of BLES to achieve low surface tensions during cyclic compressions
on the CDS, the addition of CATH-2 to BLES had a minimal effect on the biophysical
function of the exogenous surfactant even at high concentrations. AFM images suggested
that the peptides did incorporate into the film and were capable of altering the film structure.
Although there was mitigation of the bactericidal capabilities of BLES+CATH-2 when
compared to CATH-2 activity alone, the BLES+CATH-2 compound could consistently
reduce bacterial CFUs to below detectable levels, unlike all other surfactant/cathelicidin
mixtures, which showed either a large decrease or complete loss of bactericidal function in
the presence of BLES. Lastly, when intratracheally instilled into naïve mice,
BLES+CATH-2 showed no effect on animal physiology, lung edema (as measured by
protein leak), or IL-6 inflammatory response. Taken together, we conclude that it would be
feasible to develop a surfactant/cathelicidin compound that is capable of maintaining
surfactant and AMP properties and that, among the current peptides tested, BLES+CATH2 appears to be the most promising candidate for future studies to investigate the efficacy
of this therapy as an antimicrobial treatment in vivo.
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The overall rationale for our study was that surfactant can assist in the delivery of
an antimicrobial peptide into the lung, thereby overcoming some of the limitations of local
delivery of drugs in pulmonary bacterial infections. For such compounds to be effective, a
direct interaction between the surfactant and the peptide would be essential to facilitate codistribution of the two compounds when delivered to the lung. Our data, including the AFM
images of surfactant films and experiments related to the spreading of the surfactant
indicate that such direct interaction occurs, as observed by the definitive changes in
microdomain size and formation, particularly for CATH-1 and CATH-2 addition. The
peptide-surfactant interaction is likely related to the amphipathic, cationic nature of
cathelicidins, and their ability to interact with negatively charged phospholipids.
Pulmonary surfactant contains approximately 10-15% acidic phospholipids, mainly
phosphatidylglycerol (PG), with which the cathelicidins could electrostatically interact
(23). Although surfactant composition is more complex than simple lipid mixtures, the idea
of the interaction with PG is supported by studies by Sevcsik et al (24). This group utilized
binary lipid mixtures to investigate interactions between lipid mixtures and LL-37, and
found that even in binary mixtures the interaction between the cathelicidin and lipid mixture
is dictated by one of the lipids present. Although the lipid ratios in their experimental model
and those found within pulmonary surfactant are different, it is still reasonable to conclude
that the interaction observed is between the cathelicidin peptides and PG since it appears
this interaction with negatively charged phospholipids contributes to its basic mechanism
of antimicrobial activity (2). We suggest that the interaction occurring between the
surfactant phospholipids and cathelicidin peptides are affecting the individual properties of
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each component, such as the surface tension reducing functions of BLES, and bactericidal
capabilities of the cathelicidin peptides.
Whereas the above discusses a general mechanism of interaction between
cathelicidins and surfactant, we observed substantial variations among the peptides in terms
of their behavior when mixed with surfactant. Specifically, marked differences were
obtained when analyzing the antimicrobial activity when peptides were combined with
BLES, with only CATH-2 maintaining a relatively robust activity. Differences were also
observed in the microdomain shape and size via AFM when CATH-1 or CATH-2 were
added to BLES, but this was not observed for mCRAMP or LL-37. Although those
differences did not correlate with surfactant activity, these changes do provide evidence of
direct interaction, and possibly incorporation, of the peptides in the surfactant film. Other
studies have also found different lipid interactions among various AMPs. Studies by
Neville et al (25) demonstrated that the addition of LL-37 to a monolayer of DPPG caused
monolayer collapse at high surface pressures, but that addition of SMAP-29, a sheep
cathelicidin, actually improved DPPG stability upon compression. This group suggested
that this was due to the differences in peptide structures and hydrophobicity, and that
SMAP-29 was more likely to interact with the head groups of the phospholipids, while LL37 was more likely to insert into the fatty acid groups of the lipid monolayers. This may
help explain the differences observed within our study, as the peptides tested here have
different structures. It is possible that CATH-2 interacts with PG similarly to SMAP-29,
allowing CATH-2 to maintain its activity as more cationic residues are exposed to the
external environment and able to interact with bacterial membranes. Other peptides, where
the residues may be shielded by the interaction with the monolayer, would be less readily
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available to interact with the targeted bacteria, and therefore have reduced bactericidal
capabilities. One interesting feature of CATH-2 that could be related to this difference in
activity is the presence of a proline residue at amino acid position 14 that forms a kink
region between the two alpha-helical segments of the CATH-2 peptide. This kink is not
present in the other tested AMPs. It was shown previously that this hinge region is essential
for antibacterial activity since substitution of the proline residue, straightening the peptide,
resulted in highly reduced activity (26, 27). Whether this structural difference between
CATH-2 and the other AMPs is the basis of the observed differences in activity would be
an interesting future investigation, and could potentially lead to the development of
improved designer peptides for use in surfactant mixtures.
It has been repeatedly shown that intratracheal surfactant administration results in
better pulmonary distribution than aerosol and saline administration (28, 29). Exogenous
surfactant has been shown to enhance the pulmonary delivery and bioavailability of other
potential therapeutic agents such as anti-oxidants, antibiotics, corticosteroids and
adenoviral vectors (8, 30). Similar to the current experiments, several studies have
investigated the bactericidal and biophysical functions of antibiotics in the presence of
exogenous surfactant. In general, it was found using in vitro techniques that some, but not
all, of the antibiotics tested were inhibited in the presence of surfactant (31). A subsequent
in vivo study in Klebsiella pneumoniae infected mice demonstrated that intratracheal
administration surfactant with the antibiotic tobramycin had significantly reduced mortality
compared to surfactant or tobramycin alone (32). These studies provide support for the
concept of surfactant as a vehicle for drug delivery, including in the setting of bacterial
infection. Our concept of utilizing AMP-based surfactant expands on these studies, as
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cathelicidin peptides have the added advantage of lacking microbial resistance towards
them, while maintaining broad-spectrum bactericidal functions against drug-resistant
bacteria (2).
Whereas the main focus of our in vitro experiments was the maintenance of
surfactant and antimicrobial activities of potential AMP-based surfactant preparations, it
should be noted that it has also been reported that AMP can have cytotoxic effects towards
mammalian cells (26, 33, 34). Such effects could potentially limit the therapeutic
applicability of this approach. Our in vivo experiment tested this issue for the most
promising AMP-surfactant preparation, BLES+CATH-2, by instilling a therapeutic dose in
healthy mice and assessing lung physiology and inflammation. Consistent with the
reported effects for AMP, instillation of CATH-2 by itself did result in slightly elevated
lavage protein levels and IL-6 concentrations, indicative of mild pulmonary edema and
inflammation. Importantly, no such deleterious effects were observed by administration of
BLES+CATH-2. This data suggests that BLES+CATH-2 is well tolerated and safe when
instilled in a healthy lung and that mild negative side-effects of the instillation of a high
dose of CATH-2 by itself are mitigated by co-administration with surfactant.
Although our main interpretation of our spreading data was that peptides did not
inhibit this property of surfactant, it was interesting to note that the addition of all
cathelicidin peptides actually improved the adsorptive function of surfactant, as seen by a
reduced surface tension after 600 seconds, representing more surface-active material
available at the air-liquid interface. Addition of all four peptides to exogenous surfactant
led to significantly lower surface tension values reached after 600 seconds. It is possible
that these findings are related to the ability of cathelicidin peptides to penetrate bacterial
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membranes. In the context of surfactant this would imply that the peptides act as “bilayer
breakers” thereby enhancing the ability of surfactant lipids to adsorb to the interface. This
is similar to the proposed mechanisms by which the two hydrophobic surfactant proteins,
SP-B and SP-C, are thought to enhance surfactant adsorption (35, 36). Interestingly,
isolated SP-B has been reported to have antimicrobial activity as well (37). Although this
activity was completely mitigated by the interaction with surfactant lipids, the finding does
support the concept that there may be shared biophysical properties between AMPs and
surfactant properties in terms of lipid interaction (38).
In conclusion, our results support the proof of concept that AMP-based surfactant
can be utilized for the therapy of bacterial infections. It appears that the interaction between
cathelicidins and surfactant varies and among the four peptides tested, CATH-2 would be
optimal for further testing. The current observations have been limited to in vitro studies,
and in vivo safety studies. Future studies are required to test the efficacy of this compound,
by itself as well as in combination with other drugs, in an animal model of bacterial
pneumonia.
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Chapter 3: Administration of Pseudomonas aeruginosa
killed by chicken cathelicidin-2 prevents lung
inflammation in vivo
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3.1 Introduction
Pseudomonas aeruginosa is an opportunistic gram-negative bacteria, which is
commonly found in patients with cystic fibrosis (CF), non-CF bronchectasis, ventilatorassociated pneumonia, or patients that are immunocompromised due to various underlying
comorbidities (1–4). Treatment of P. aeruginosa airway infections, particularly in chronic
disease states such as CF, are made difficult due to the emergence of antibiotic resistance
(1, 5–7). Chronic infection by P. aeruginosa can lead to tissue injury, ultimately resulting
in progressive lung dysfunction, respiratory failure, and death (8–12). Due to the increasing
prevalence of antibiotic resistance, and the lack of new therapeutics being produced in the
pharmaceutical pipeline (13), the development of novel antimicrobials to combat these
infections are desperately needed.
To address this issue, cathelicidins, a family of host defense peptides with direct
antimicrobial activity, are being explored as potential alternatives for antibiotics. These
peptides, which are endogenously produced by multiple cell types, including epithelial
cells, macrophages, monocytes, and neutrophils, have a broad spectrum bactericidal
activity and are less susceptible to classical mechanisms of bacterial resistance (14).
Furthermore, cathelicidins exhibit a variety of immunomodulatory functions, which may
provide additional benefits in their use to combat pulmonary infections (15).
One specific cathelicidin, the chicken cathelicidin CATH-2, has previously been
identified as a strong candidate for therapeutic use. This peptide has been demonstrated to
kill P. aeruginosa in physiologically relevant conditions (16) and was shown to retain
significant antimicrobial function when combined with a pulmonary surfactant vehicle for
lung targeted delivery (17). Recent in vitro studies have demonstrated that the killing of
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bacteria by CATH-2 can occur without inducing a marked inflammatory response (18, 19).
This “silent killing” activity was demonstrated by incubating a macrophage cell-line with
either CATH-2-, heat-, or antibiotic-killed Escherichia coli, or Salmonella enteritidis (19).
Macrophages exposed to the bacterial products from either heat- or antibiotic-killed
bacteria responded by producing high levels of inflammatory mediators such as IL-6 and
TNF-α; as compared to the CATH-2-killed bacteria, which elicited minimal inflammatory
cytokine production. Based on the clinical observations that chronic maladaptive
inflammatory responses can lead to indiscriminate tissue damage and expedited lung injury,
as observed in CF patients (19–22), this silent-killing property of CATH-2 may further
extend its clinical potential.
To date, silent killing by CATH-2 has only been observed in vitro. The in vivo
environment within the lung is more complex as inflammation will involve multiple celltypes, cell migration and activation, physiologic lung dysfunction, and a local inflammatory
environment that may vary between different airways and alveoli. Therefore, the objective
of the current study was to determine the role of CATH-2 in dampening the inflammatory
response induced by killed bacteria in vivo. It is hypothesized that CATH-2-killed bacteria
will elicit a reduced inflammatory response after in vivo intratracheal instillation as
compared to heat and antibiotic killed bacteria.
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3.2 Materials and Methods
Preparation of killed bacteria for in vivo analysis
An overnight culture of P. aeruginosa ATCC 27853 was diluted 1/10 in tryptic soy
broth (TSB). The optical density was measured, and bacteria were further diluted in sterile
saline to reach an initial concentration of approximately 2x106 CFU/ml. Subsequently, the
bacteria were killed by CATH-2 (20 µM at 37°C for one hour), heat (90°C for one hour),
or gentamicin (1 mg/ml gentamicin at 37°C for one hour). In a subset of bacteria killed by
heat or gentamicin, 20 µM CATH-2 was added to the bacterial mixture before instillation.
After intratracheal instillation, part of the bacterial solutions was plated via spot plating on
tryptic soy agar (TSA), and incubated overnight at 37°C. The plates were examined the
following morning to ensure complete bacterial killing.

In vivo analysis following administration of killed bacteria
Male C57Bl/6 mice (Charles River, Sherbrooke, Qc, Canada), weighing 23-32 g,
were used for this experiment. All animal procedures were approved by the Animal Use
Subcommittee at the University of Western Ontario, and followed the approved guidelines
described by the Canadian Council of Animal Care. Mice were anesthetized by
intraperitoneal (IP) injection of ketamine (100 – 125 mg/kg body weight) and
dexmedetomidine (0.5 mg/kg BW), and then intubated using a 20G catheter with the aid of
a fiber-optic stylet (BioLite intubation system for small rodents, BioTex, Inc., Houston,
Texas, USA). Once intubated, mice were randomized into treatment groups and instilled
with 50 µl of a) CATH-2-killed bacterial preparations, b) heat-killed bacteria, c) heat-killed
bacteria supplemented with CATH-2, d) gentamicin-killed bacteria, e) gentamicin-killed
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bacteria supplemented with CATH-2, or f) instilled with an air bolus (naïve controls). Mice
were extubated following successful instillation and were allowed to breathe spontaneously
for six hours. After six hours, the mice were euthanized by IP injection of sodium
pentobarbital (110 mg/kgBW) and dissection of the descending aorta. The animals were
placed on a FlexiVent© in order to measure lung compliance and elastance. Following
these measurements, whole lung bronchoalveolar lavage fluid (BALF) was collected by 3
x 1 ml aliquots of sterile saline. The whole lung lavage was immediately centrifuged at 400
x g at 4°C for 10 minutes, and the pellet was collected for cell analysis, while the
supernatant was collected and used to measure protein content, and cytokine analysis. A
sample of the supernatant was centrifuged at 40 000 g at 4°C for 15 minutes, in order to
separate pulmonary surfactant subfractions. Pulmonary surfactant concentrations were
determined using a modified Duck-Chong assay as previously described (23). Total cell
counts and differential cell analysis of the cells obtained in the lavage was done as
previously described (24). Protein content of the lavage fluid was measured using a Micro
BCA protein assay kit (Pierce, Rockford, Ill., USA), as per manufacturer’s instructions.
Concentrations of mouse cytokines were measured using multiplexed immunoassay kits
according to the manufacturers’ instructions (R&D Systems, Minneapolis, MN). A BioPlex 200 readout system was used (Bio-Rad), which utilizes Luminex® xMAP fluorescent
bead-based technology (Luminex Corporation, Austin, TX). Cytokine levels (pg/ml) were
automatically calculated from standard curves using Bio-Plex Manager software (v. 4.1.1,
Bio-Rad).

Statistical Analysis
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Analysis of the inflammatory response induced by killed bacteria were performed by oneway measure analysis of variance (ANOVA) followed by Tukey post-hoc test. Means were
reported ± standard error of the mean. Values were considered statistically significant at a
probability value < 0.05.

95

3.3 Results
Effect of killed bacteria administration on respiratory function
Six hours after receiving intratracheal instillation of killed bacteria, lung physiology
was measured via FlexiVent. There was no significant difference between any of the
treatment groups in any lung function measurements, including lung compliance, elastance,
or total lung capacity (Table 3.1). Bronchoalveolar lavage fluid volumes were not
significantly different between treatment groups (Table 3.2). Protein concentrations from
lung lavage of animals receiving gentamicin-killed bacteria supplemented with CATH-2
were significantly increased compared to naïve controls, but there was no significant
difference among the other treatment groups (Table 3.2).
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Treatment Group

Weight (g)

Lung Function
Compliance
(ml/cmH2O)
0.0578 ± 0.0029

Elastance
(cmH2O/ml)
17.54 ± 0.92

Naïve

29.5 ± 0.66

Total Lung
Capacity (ml)
0.794 ± 0.041

CATH-2-Killed

28.0 ± 1.40

0.752 ± 0.048

0.0529 ± 0.0041

19.41 ± 1.62

Heat Killed

27.8 ± 0.72

0.777 ± 0.056

0.0558 ± 0.0033

18.14 ± 1.18

Heat+CATH-2

27.8 ± 0.91

0.812 ± 0.034

0.0557 ± 0.0023

18.09 ± 0.73

Gentamicin Killed

28.9 ± 0.65

0.862 ± 0.068

0.0581 ± 0.0031

17.51 ± 0.93

Gent+CATH-2

27.8 ± 0.57

0.845 ± 0.031

0.0588 ± 0.0025

17.11 ± 0.71

Table 3.1 Weight and lung function measurements of mice that were intratracheally
administered killed bacteria. Values are expressed as mean ± SEM. (n=5-6)
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Total Surfactant
(mgPL/kg BW)

Surfactant Analysis
Small Aggregate
(mgPL/kg BW)

Large Aggregate
(mgPL/kg BW)

2.82 ± 0.07

8.82 ± 0.71

5.17 ± 0.45

3.23 ± 0.57

14.04 ± 0.72

CATH-2
Killed

2.75 ± 0.09

8.82 ± 0.82

5.65 ± 0.34

3.14 ± 0.49

21.60 ± 3.72

Heat Killed

2.88 ± 0.06

7.85 ± 0.22

3.87 ± 0.25

2.53 ± 0.35

14.44 ± 1.38

2.66 ± 0.12

9.72 ± 1.04

5.17 ± 0.26

2.94 ± 0.77

16.63 ± 2.21

2.88 ± 0.07

9.12 ± 1.24

4.67 ± 1.04

3.24 ± 0.63

15.74 ± 2.53

2.68 ± 0.14

7.94 ± 1.12

3.89 ± 0.58

2.73 ± 0.20

34.47 ± 9.56a

Treatment
Group

Lavage
Volume (ml)

Naïve

Heat+
CATH-2
Gentamicin
Killed
Gent+
CATH-2

Protein Content
(mg/kgBW)

Table 3.2 Lavage volume, surfactant analysis, and protein content from BALF of mice
instilled killed bacteria. Values are expressed as mean ± SEM. (n=5-6)
a

p < 0.05 vs. naïve treatment group.
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CATH-2-killed bacteria elicit reduced total cell counts and reduced neutrophil influx
Instillation of either heat-killed or gentamicin-killed bacteria caused a significant
inflammatory response, with significant increases in total cells in the BALF compared to
naïve animals (Figure 3.1). Pseudomonas aeruginosa killed by 20 µM of CATH-2 elicited
a reduced inflammatory response. The number of cells recovered from the BALF of
animals instilled with CATH-2-killed bacteria was a significantly reduced compared to
gentamicin-killed bacteria. There was also a reduction in cell recruitment induced by
CATH-2-killed bacteria compared to heat-killed bacteria that did not reach statistical
significance.
In addition to reducing total cell influx, the percentage of neutrophils in the BALF
was also significantly reduced in animals treated with CATH-2-killed bacteria compared
to both heat-killed and gentamicin-killed bacterial treatments (Figure 3.2).

Addition of CATH-2 to heat-killed bacteria downregulates cell influx
Heat-killed P. aeruginosa that was supplemented with 20 µM CATH-2 after
bacterial killing decreased the inflammatory response induced by heat-killed bacteria alone.
There was a trend for reduced cellular influx between heat-killed and heat-killed+CATH2 treated animals (Figure 3.1), and the total cell counts for animals administered heat-killed
bacteria + CATH-2 were similar to naïve treatment groups. Supplementation of CATH-2
to gentamicin-killed bacteria did not have the same anti-inflammatory effect. There was no
significant difference in total cell counts between gentamicin-killed bacteria and
gentamicin-killed+CATH-2 treatment groups.
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Similarly, the supplementation of CATH-2 to heat-killed bacteria induced a
significant reduction in percentage of neutrophils in the BALF compared to heat-killed
bacteria alone, reducing levels to the values observed in animals administered CATH-2killed bacteria (Figure 3.2). The percent of neutrophils recovered from gentamicinkilled+CATH-2 treated animals were not reduced compared to gentamicin-killed bacteria
(Figure 3.2).
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Figure 3.1
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Figure 3.1. Total cells recovered from whole lung BALF of mice instilled killed bacteria.
(n=5-6) *p < 0.05.

101
Figure 3.2
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Figure 3.2. Percentage of neutrophil cells recovered from whole lung BALF of mice
instilled killed bacteria. (n=5-6) *p<0.05; **p<0.01.
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CATH-2-killed bacteria elicited reduced inflammatory cytokine release
Bacteria killed by CATH-2 induced significantly less cytokine release compared
to both heat-killed and gentamicin-killed bacteria. Levels of TNF-α, IL-6, and KC were
significantly reduced in the BALF of animals receiving CATH-2-killed bacteria compared
to animals receiving either heat- or gentamicin-killed bacteria, and IL-12p70, G-CSF, MIP2, IL-23p19, and MMP-9 were significantly reduced compared to animals administered
gentamicin-killed bacteria alone (Figure 3.3).
Similar to cellular influx data, the addition of CATH-2 to heat-killed bacteria was
able to reduce the inflammatory cytokine production induced by heat-killed bacteria.
Levels of TNF-α and KC were significantly reduced compared to the heat-killed bacteria
group alone, while reduction trends persisted for the majority of inflammatory cytokines.
On the other hand, there was no significant difference between animals administered
gentamicin-killed bacteria supplemented with CATH-2 and gentamicin-killed bacteria
alone in many cytokines, including TNF-α, KC, IL-12p70, G-CSF, MIP-2, or MMP-9. In
fact, IL-6 and IL-23p19 showed increases in release from animals administered gentamicinkilled+CATH-2 compared to gentamicin-killed bacteria alone (Figure 3.3).
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Figure 3.3
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Figure 3.3. Cytokine and chemokine concentrations from whole lung BALF. (n=5-6)
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3.4 Discussion
In this study, we have shown that CATH-2 is able to kill a clinically-relevant lung
pathogen, P. aeruginosa, and intratracheal instillation of these killed bacteria does not
induce a marked inflammatory response, as observed with heat or conventional antibiotic
killed bacteria. Compared to other methods of bacterial killing, the bacteria killed by this
cathelicidin peptide induced a significantly dampened inflammatory response after
instillation, through the reduced recruitment of leukocytes and decreased concentrations of
pro-inflammatory cytokines in the lavage fluid. Furthermore, the addition of CATH-2 to
heat-killed bacteria eliminated the exacerbated inflammatory response induced by heatkilled bacteria, although this anti-inflammatory effect was not observed with gentamicinkilled bacteria.
To address our hypothesis that CATH-2-killed bacteria will elicit a reduced
inflammatory response after in vivo intratracheal instillation, we utilized a model of
intratracheal instillation of killed bacteria into healthy mice. None of the experimental
groups showed any sign of lung dysfunction as indicated by measurements of compliance,
elastance, surfactant composition, as well as total protein in the lavage. This data suggests
that the inflammatory responses measured in this experiment were in response to the
instilled bacterial products and peptide, and not an indirect effect due to tissue injury within
the lung. The use of killed bacteria allowed for the investigation of CATH-2’s ability to
modulate the inflammatory responses induced by products released after bacterial death,
without the confounding factors associated with toxin production or epithelial damage
induced by live bacteria (3, 11). Therefore, this provides evidence for the role of
cathelicidin peptides in modulating immunity and inflammatory responses after bacterial
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clearance, as observed through the changes in cell recruitment and inflammatory cytokine
production.
The main finding of this study is that the mechanism of bacterial death affected the
inflammatory response in vivo. While heat-killed and gentamicin-killed bacteria were able
to induce robust inflammatory responses, CATH-2-killed bacteria induced a significantly
lower inflammatory response, as fewer neutrophils were recruited, and the concentration
of inflammatory cytokines recovered from the BALF was significantly lower for multiple
different markers. CATH-2’s ability to kill bacteria without inducing an inflammatory
response has previously only been documented in vitro, as it was shown that treatment of
macrophages with peptide-killed E. coli, S. enteritidis, or P. aeruginosa exhibit a reduced
inflammatory response after co-incubation (19). Our data provides clear evidence that this
phenomenon also occurs in the multicellular in vivo environment within the lung. Taken
together, these studies strongly support the conclusion that the cathelicidin peptide CATH2 can not only kill bacteria directly, but is also able to dampen the immunogenic response
induced by the bacterial components, such as endotoxins and other bacterial structures,
released upon bacterial cell death.
A second important finding of this study was the ability of CATH-2 to downregulate the inflammatory responses caused by heat-killed bacteria. The fact that CATH-2
supplementation was able to return inflammation to basal levels adds evidence of the ability
of CATH-2 to directly modulate the inflammatory response induced by bacterial products,
and that this effect is can be independent from its killing activity. However, this down
regulation was not observed when CATH-2 was supplemented to gentamicin-killed
bacteria, where in fact an exacerbated inflammatory response was observed. While
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gentamicin has been mainly studied in nephrotoxicity and ototoxicity due to its common
side effects, the mechanisms of action to induce both apoptosis and necrosis in vivo involve
the accumulation of high levels of gentamicin intracellularly, causing non-specific
activation of multiple apoptotic and necrotic pathways (25). It is possible that the high
concentration of gentamicin (1 mg/ml) that was used to kill the bacteria induced some of
these cytotoxic effects once administered intratracheally. Recent studies in our lab have
demonstrated that bacteria killed with a lower dose of gentamicin induced inflammatory
effects that were downregulated by co-administration of CATH-2, similar to heatkilled+CATH-2 observations (Brandon Baer, unpublished results). Overall, these results
require further investigation into the mechanism of action, in order to understand the
potential of cathelicidins as active therapeutics in co-treatment with conventional
antibiotics.
Initial interest in cathelicidins for therapeutic development focused solely on their
direct bactericidal functions (26, 27). CATH-2 has been repeatedly shown to possess
bactericidal activity against multiple different bacterial strains under a wide variety of
environmental conditions in in vitro settings (28–31). Unlike other cathelicidin peptides,
such as human LL-37, which lose bactericidal activity under physiologic salt conditions
(32), CATH-2 appears to be relatively insensitive to a variety of different conditions,
including serum and high ionic environments. The ability of CATH-2 to maintain
bactericidal activity provides evidence for its potential direct bactericidal role in vivo (16,
17). Regardless of their degree of bactericidal activity, it is abundantly clear that
cathelicidin peptides can be directly responsible for the clearance of bacterial infection, and
that a loss/decrease in peptide can lead to a strong reduction in immune response and
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bacterial clearance (33, 34). From the data presented here, we suggest that CATH-2 has the
ability to both kill bacteria, as well as dampen inflammatory responses after stimulation
with the bacterial products. This direct bactericidal activity along with the ability to inhibit
the inflammatory response induced by killed bacteria is key in regulating proper immune
responses. These regulatory functions prevent excessive inflammatory responses, and
indiscriminate cytotoxic damage caused by neutrophil migration and activation, commonly
associated with chronic infection states (35–38).
One of the common immunomodulatory functions of various cathelicidin peptides
is their (relatively) conserved ability to bind and neutralize bacterial endotoxins, such as
LPS, thereby silencing the downstream inflammatory signalling process (39–41). In
combination with these previous observations, our results suggest that, in addition to
CATH-2 direct antimicrobial activity via bacterial membrane binding and cell lysing, there
is a potential anti-inflammatory activity of CATH-2 via binding to the LPS released from
the bacterial membrane, thereby inhibiting cellular activation through TLR 4. Additional
studies have also shown that cathelicidins are able to down-regulate signalling through
other TLR pathways such as TLR 5 (42). As P. aeruginosa contains flagellin, the main
agonist of TLR 5, it is possible that CATH-2 has some immunomodulatory interaction with
this pathway as well, similar to that observed with other cathelicidin peptides.
In a natural host immune response, activation of TLRs by bacterial by-products
elicits a series of complex intracellular cascades, with the focus on translocation and
activation of the nuclear factor-κB (NF-κB) (43). This transcription factor is found in all
major cell types, and is one of the transcription factors responsible for this proinflammatory cytokine release (44, 45). The goal of most inflammatory cytokines released
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is the recruitment of circulating neutrophils to aid in the removal of an invading pathogen
(46). However, in patients with underlying diseases, such as cystic fibrosis, this recruitment
can be detrimental as neutrophils release a vast array of toxins and oxidizers, which act to
kill bacteria, but can damage host tissues in the process (47). The ability of CATH-2 to
prevent this signalling caused by bacterial debris, which is found throughout the CF airways
over the course of a patient’s life, would therefore be able to protect tissue damage caused
by the exacerbated inflammatory response often observed (47).
The ability to both kill clinically-relevant pathogens, as well as reduce the ensuing
inflammatory environment, are essential properties for the development of CATH-2 as a
therapeutic in cystic fibrosis. The CF microenvironment is incredibly complex, and is
marred by the combination of a non-functional mucociliary elevator (22), incompetent
innate immune responses (47), ineffective removal of apoptotic cells and debris (48), all
cumulating in a tissue-damaging pro-inflammatory environment (47, 49, 50). Therefore,
these studies provide evidence for the potential therapeutic use of CATH-2 in the treatment
of P. aeruginosa infection in CF patients. Based on these experiments, CATH-2 may be
developed in order to both reduce the bacterial load via direct bactericidal activity, as well
as minimize the inflammatory impact of the bacterial debris after death. These two
properties could make CATH-2 a powerful future therapeutic option in the treatment of
CF-associated pneumonia.
In conclusion, CATH-2 is an effective bactericidal agent, and bacteria killed
through this peptide result in a diminished inflammatory response in vivo, presumably
enabling the host organism to prevent an inflammatory environment after the colonizing
bacteria are cleared. This anti-inflammatory role adds merit to cathelicidins’ potential as
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therapeutic antimicrobial agents in the future. However, their pro-inflammatory role with
bacteria and conventional antibiotics raises questions as to the mechanism of interaction
between these compounds, and requires further investigation before the two can be used
effectively together.
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Chapter 4: The antibacterial and anti-inflammatory
activity of an exogenous surfactant preparation fortified
with chicken cathelicidin-2 against cystic fibrosis
associated pathogens
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4.1 Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused by defects in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene, which leads to alterations in
the respiratory epithelial cilia and increased viscosity of the airway-surface mucosal layer.
As a consequence of the inability to efficiently clear airway secretions, chronic airway
colonization of bacterial pathogens ensues, resulting in a vicious circle of repeated lower
respiratory tract infections, inflammation and tissue remodelling (1, 2). The prolonged use
of oral or systemic antibiotics used to treat infections in these patients frequently results in
airway colonization of multi-drug resistant bacteria, which represents an independent
predictor of adverse clinical outcomes, decline in lung function and death (2–4). In
addition, the complex pro-inflammatory environment induced by chronic bacterial airway
infections further promotes airway epithelial cell injury and airway remodelling (5–11).
Over time, the development of antibiotic-resistant bacterial infections coupled with,
chronic, maladaptive inflammation poses a significant therapeutic challenge. Novel
therapies are urgently needed in order to improve the quality of life for this challenging
patient population.
Cathelicidins are a class of host-defense peptides that have been investigated for
their potential therapeutic use against antibiotic-resistant infections (12). Cathelicidins are
essential components of the innate immune system that are highly conserved across
multiple mammalian species and have been shown to possess both direct bactericidal
activity and immunomodulatory activity including alterations of inflammatory cytokine
production and immune cell migration (13–21). Due to their broad-spectrum antimicrobial
and immunomodulatory effects, these peptides may represent an excellent alternative to

118
conventional antimicrobials and are currently being investigated for use in patients with CF
(22–25).
In order to optimize the delivery of therapeutics throughout the airways, exogenous
surfactant has been investigated as a potential delivery vehicle due to its ability to improve
distribution of lung targeted therapeutics to peripheral lung regions (26–28). The use of
exogenous surfactant has been thoroughly investigated and currently exists as the standard
of care for neonates with surfactant deficiency in the setting of neonatal respiratory distress
syndrome, and is therefore safe and well tolerated (26, 28, 29). Our group has previously
investigated a combined approach using a chicken cathelicidin, CATH-2, together with a
commercially available exogenous surfactant preparation, bovine lipid-extract surfactant
(BLES), and has shown that BLES+CATH-2 maintains both excellent surfactant
biophysical properties, antimicrobial activity, and was tolerated

when administered

intratracheally to naïve mice (30). Therefore, the objective of the current study was to assess
the specific antimicrobial or anti-inflammatory properties of BLES+CATH-2 for the
treatment of CF related lung infections. It was hypothesized that BLES+CATH-2 will
exhibit bactericidal activity against multi-drug resistant bacteria obtained from CF patients
and additionally, that BLES+CATH-2 will reduce the inflammatory response induced by
bacterial products in an in vivo model of pulmonary inflammation.
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4.2 Materials and Methods
Clinical isolates
Clinical bacterial isolates were obtained from nine adult CF patients attending the
London Health Sciences Centre outpatient CF clinics and protocols were approved by the
Human Ethics subcommittee at The University of Western Ontario. Isolated bacteria were
stored in citrate glycerol solutions at -80°C, and were isolated, identified and sub-cultured
onto chocolate blood agar (CBA) prior to use in study. The samples obtained included eight
P. aeruginosa, one A. xylosoxidans, and three S. aureus bacterial strains isolated from CF
sputum samples. Antibiotic sensitivities of the isolated bacteria were obtained according to
Clinical Laboratory Standards Institute procedures.

Bactericidal activity against clinical bacteria
Bactericidal activity was measured using a spot plating assay. In brief, an overnight
culture of bacteria grown in TSB diluted in Müeller-Hinton Broth (MHB). The turbidity
was adjusted to 0.5 McFarland, followed by an additional 50x dilution in either MHB or
saline. Subsequently, 50 µl of bacteria and 50 µl of either CATH-2 or BLES+CATH-2 (0200 µM of CATH-2; 10 mg/ml phospholipid of BLES) was added to a polypropylene
coated 96-well plate, and incubated at 37°C for three hours with no shaking. After
incubation, the bacterial suspension was serially diluted 10-10 000-fold, and 10 µl of each
dilution was spot plated in triplicate on CBA plates. These plates were incubated overnight,
and colonies on the plates were counted the following morning. Minimum bactericidal
concentration (MBC) was determined as the minimum CATH-2 concentration at which no
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bacterial growth was observed, corresponding to a bacterial concentration of less than 100
CFU/ml.

In vivo antimicrobial-independent inflammation model
One mucoid strain of P. aeruginosa (Patient 6) and one S. aureus (Patient 4) (Table
4.1) species were selected for use in this study. An overnight culture of P. aeruginosa or S.
aureus was diluted 1/10 in MHB. The optical density was measured using a
spectrophotometer, and bacteria were further diluted in MHB to reach an initial
concentration of approximately 2x106 CFU/ml. Subsequently, the bacteria were killed by
heat (90°C for one hour). In a subset of bacteria killed by heat, CATH-2 (20 µM) or
BLES+CATH-2 (10 mg/ml phospholipid; 100 µM peptide) was added to the killed-bacteria
mixture prior to instillation. The dead-bacteria solutions were plated via spot plating on
chocolate agar, and incubated overnight at 37°C to confirm complete bacterial killing of
instilled samples.
The killed bacteria were then instilled into male C57Bl/6 mice (Charles River,
Sherbrooke, Qc, Canada) as previously described in Chapter 3. Once intubated, mice were
randomized to receive a 50 µl instillation of either heat-killed bacteria, heat-killed bacteria
+ CATH-2, heat-killed bacteria + BLES+CATH-2, or MHB without bacteria as a negative
control. Mice were extubated following successful instillation, followed by a subcutaneous
injection of 0.5 ml of saline and were allowed to breathe spontaneously for six hours.
Following the 6-hour time period, the mice were euthanized by sodium pentobarbital
overdose (110 mg/kgBW) and severance of the descending aorta, and were placed on a
FlexiVent© to measure quasi-static lung compliance and elastance. Following Flexivent
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measurements, whole lung bronchoalveolar lavage fluid (BALF) was collected by flushing
the lungs with 3 aliquots of 1 ml sterile saline. The whole lung lavage was immediately
centrifuged at 400 x g at 4°C, and the pellet was collected for cell analysis, while the
supernatant was collected and used to measure protein content and cytokine quantification.
Differential cell analysis of the cell pellets obtained from the lavage was done as
previously described (31). Protein content of the lavage fluid was measured using a Micro
BCA protein assay kit (Pierce, Rockford, Ill., USA), according to the manufacturer’s
instructions. Concentrations of mouse cytokines were measured using multiplexed
immunoassay kits according to the manufacturers’ instructions (R&D Systems,
Minneapolis, MN). A Bio-Plex 200 readout system was used (Bio-Rad), which utilizes
Luminex® xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX).
Cytokine levels (pg/ml) were automatically calculated from standard curves using Bio-Plex
Manager software (v. 4.1.1, Bio-Rad).

Statistical Analysis
Analysis of the inflammatory response induced by heat-killed P. aeruginosa and S.
aureus was performed by a one-way measure of variance (ANOVA) followed by Tukey
post-hoc test. Means were reported ± standard error of the mean, and values were
considered statistically significant at a probability value (p) < 0.05.
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4.3 Results
Patient Data
In vitro bacterial-resistance patterns were obtained using protocols performed by
the London Health Science Centre Clinical Microbiology Laboratory and clinical
characteristics of cystic fibrosis patients are shown in Table 4.1. Patients ranged between
24 and 57 years of age. Severity of disease was variable between patient groups, with
FEV1PRED between 28 and 87%. Two-thirds of patients were colonized with at least one
strain of P. aeruginosa, 3 out of the 9 patients were infected with S. aureus, and one patient
was infected with A. xylosoxidans. Of the eight P. aeruginosa isolates investigated, 50%
presented with a mucoid phenotype. Of all bacteria investigated, 58% were resistant to at
least two conventional antibiotics. Bacterial resistance did not correlate with age, or disease
severity.
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Patient No.
1
2

Sex (M/F)
F
M

Age (years)
57
24

Weight (kg)
60.6
72

BMI (kg/m2)
22.5
25.3

FEV1 %Pred
39
50

3

M

50

57

19.3

43

Achromobacter xylosoxidans

4

F

35

62

22.4

87

Staphylococcus aureus
Pseudomonas aeruginosa (muc)
Pseudomonas aeruginosa

5

F

44

59

22

73

Pseudomonas aeruginosa (muc)

6
7

F
M

40
37

57
52.5

20.9
19.3

52
28

Pseudomonas aeruginosa (muc)
Pseudomonas aeruginosa (muc)

8

M

27

62

18.7

48

Staphylococcus aureus

9

F

31

40.5

18.2

55

Pseudomonas aeruginosa (muc)

Bacteria
Pseudomonas aeruginosa
Staphylococcus aureus

Pseudomonas aeruginosa

Resistance Profiles
NR
Clindamycin, Erythromycin R
Gentamicin, Meropenem,
Tobramycin R; Imipenem,
Ciprofloxacin I
NR
NR
Tobramycin, Gentamicin R
Amikacin, Gentamicin,
Meropenem, Ciprofloxacin,
Tobramycin R
Gentamicin, Tobramycin R
NR
Clindamycin, Erythromycin,
Cloxacillin R
NR
Meropenem R; Ciprofloxacin,
Gentamicin I

Table 4.1. Resistance profiles of clinical samples. Resistance profiles were obtained by London Health Sciences Centre Clinical
Microbiology Laboratory using clinical laboratory and standards institute protocols. Muc = mucoid phenotype. NR = no resistance
identified, R = resistant, I = impaired activity.
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Bactericidal activity of BLES+CATH-2 against bacteria from cystic fibrosis patients
After in vitro incubation of either CATH-2 or BLES+CATH-2 with the isolated
bacteria, it was observed that CATH-2 alone exhibited potent bactericidal activity against
all P. aeruginosa strains tested, regardless of antibiotic resistance profile of the bacteria
(Figure 4.1). The MBC of CATH-2 against all P. aeruginosa strains was between 2.5 – 10
µM. BLES+CATH-2 bactericidal activity against the clinical P. aeruginosa was much
more variable, with bacterial recovery varying between a 3-log reduction to complete
bacterial killing. Overall, BLES+CATH-2 MBC values were typically 100 µM, and as low
as 50 µM against select CF-derived isolates (Figure 4.1).
Similar to P. aeruginosa, CATH-2 exhibited potent antimicrobial activity against
all strains of S. aureus tested. CATH-2 again showed bactericidal activity against all S.
aureus isolates investigated, with MBC values between 5 – 10 µM for all strains
investigated (Figure 4.2). BLES+CATH-2 showed consistent bactericidal activity, and
achieved MBC values at 100 µM against all S. aureus isolates tested. Bactericidal activity
of CATH-2 and BLES+CATH-2 against A. xylosoxidans was similar to activity observed
against both P. aeruginosa and S. aureus (Figure 4.3).
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Figure 4.1
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Figure 4.1. Antimicrobial assays of CATH-2 and BLES+CATH-2 against P. aeruginosa
isolates.

The bacteria were suspended in MHB, and then treated with various

concentrations of CATH-2 (green, solid line) or CATH-2 suspended in 10 mg/ml
phospholipid of BLES (red, dotted line). (n=3)
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Figure 4.2
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Figure 4.2. Antimicrobial assays of CATH-2 and BLES+CATH-2 against S. aureus
isolates. The bacteria were suspended in MHB, and then treated with various concentrations
of CATH-2 (green, solid line) or CATH-2 suspended in 10 mg/ml phospholipid of BLES
(red, dotted line). (n=3)
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Figure 4.3.
Patient 3 - A. xylosoxidans
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Figure 4.3. Antimicrobial assays of CATH-2 and BLES+CATH-2 against A. xylosoxidans.
The bacteria were suspended in MHB, and then treated with various concentrations of
CATH-2 (green, solid line) or CATH-2 suspended in 10 mg/ml phospholipid of BLES (red,
dotted line). (n=3)
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Bactericidal activity of CATH-2 and BLES+CATH-2 in saline
Figure 4.4 demonstrates the bactericidal activity of CATH-2 and BLES+CATH-2
in saline against the same CF-derived bacteria used above. Against P. aeruginosa, CATH2 was an effective antimicrobial agent, and was able to reduce bacterial recovery to below
detectable levels at concentrations between 5-10 µM. The addition of BLES severely
inhibited bactericidal activity, as BLES+CATH-2 was unable to reduce any strain of
bacteria to below detectable levels, even at 100 µM concentrations.
CATH-2 possessed minimal bactericidal activity against either S. aureus or A.
xylosoxidans, as it was only able to reduce bacteria to below detectable levels in one strain
(Patient 8 S. aureus) at a concentration of 50 µM. While increasing doses of CATH-2 were
able to reduce some bacterial recovery (2-3 log reduction), BLES+CATH-2 exhibited no
detectable bactericidal activity against any isolates of S. aureus or A. xylosoxidans.
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Figure 4.4
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Figure 4.4. Representative antimicrobial assays of CATH-2 and BLES+CATH-2 against
various bacterial species isolated from CF patient sputum in saline. The bacteria were
suspended in saline, and then treated with various concentrations of CATH-2 (green, solid
line) or CATH-2 suspended in 10 mg/ml phospholipid of BLES (red, dotted line). (n=3)
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In vivo inflammation induced by killed cystic fibrosis derived bacteria
To investigate the potential anti-inflammatory effects of BLES+CATH-2, we used
a previously reported model of inflammation induced by killed bacteria as described in
Chapter 3. After instillation of the killed bacteria, there were no significant differences in
lung compliance, elastance or protein content found within the lungs of instilled animals
(Table 4.2). We observed a significant increase in total cell counts recovered in the BALF
from animals that received intratracheally-administered heat-killed P. aeruginosa
compared to control treatments (Figure 4.5a). We demonstrated that there was no increase
in total cells recovered from animals administered CATH-2-killed P. aeruginosa compared
to animals that did not receive killed bacteria. The differential cell counts demonstrated a
significant increase in neutrophils from animals administered heat-killed P. aeruginosa
compared to control animals, which was not observed in animals administered CATH-2killed bacteria (Figure 4.5b). Supplementation of heat-killed P. aeruginosa with either
CATH-2 or BLES+CATH-2 significantly reduced total cells in the BALF, including
significantly lower number of neutrophils compared to heat-killed control groups (Figure
4.5a). These values for heat-killed bacteria supplemented with CATH-2 or with
BLES+CATH-2 groups were not significantly different from the control group, or animals
receiving CATH-2-killed bacteria alone (Figure 4.5b). Multiplex cytokine analysis showed
that heat-killed P. aeruginosa elicited a significant increase in KC, MIP2, and GM-CSF
compared to controls, while CATH-2-killed bacteria did not (Figure 4.6). Heat-killed P.
aeruginosa supplemented with either CATH-2 or BLES+CATH-2 did not increase any of
the inflammatory cytokines measured compared to negative controls, and significantly
decreased KC concentrations compared to heat-killed bacteria. BLES+CATH-2

131
supplementation also significantly reduced MIP-2 levels compared to heat-killed P.
aeruginosa.
For S. aureus, cell counts recovered from mice administered heat-killed bacteria
were significantly higher than the negative control group (Figure 4.7a). Cell counts from
animals administered CATH-2-killed S. aureus were not statistically different from control
animals, but was not statistically different compared to animals receiving heat-killed
bacteria. Heat-killed bacteria supplemented with CATH-2 or BLES+CATH-2 were
significantly reduced compared to heat-killed alone (Figure 4.7a). Heat-killed S. aureus
supplemented with CATH-2 or BLES+CATH-2 also had a significantly lower recovery of
neutrophils compared to heat-killed bacteria alone (Figure 4.7b). Despite the differences in
cells recovered and cell differentials, there was no increase in any cytokine production after
administration of heat-killed S. aureus compared to the control treatment, and no significant
difference in any cytokine investigated for animals administered killed S. aureus (Figure
4.8).
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Treatment
Control
P. aeruginosa
Heat-killed
CATH-2-killed
Heat+CATH-2
Heat+(BLES+CATH-2)
S. aureus
Heat-killed
CATH-2-killed
Heat+CATH-2
Heat+(BLES+CATH-2)

21.62 ± 3.0

Quasi-Static
Compliance
(ml/cmH2O)
0.0777 ± 0.016

Quasi-Static
Elastance
(cmH2O/ml)
13.28 ± 2.70

20.56 ± 9.7
24.80 ± 8.2
19.44 ± 5.9
17.58 ± 4.9

0.0718 ± 0.0080
0.0676 ± 0.0071
0.0755 ± 0.0069
0.0801 ± 0.0064

14.08 ± 1.76
14.92 ± 1.55
13.35 ± 1.34
12.56 ± 1.07

20.79 ± 5.2
22.08 ± 4.4
20.98 ± 7.8
18.39 ± 8.0

0.0754 ± 0.0132
0.0739 ± 0.0066
0.0736 ± 0.0080
0.0712 ± 0.0071

13.70 ± 3.02
13.62 ± 1.24
13.74 ± 1.64
14.16 ± 1.46

Protein Content
(mg/kg BW)

Table 4.2. Protein content obtained from BALF after whole lung lavage, and quasi-static
compliance and elastance as measured by FlexiVent. Values presented as mean ± SEM. (n=57)
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Figure 4.5
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Figure 4.5. Cell counts and differentials cell counts of animals administered heat-killed P.
aeruginosa obtained from Patient 6. a) Total cell counts obtained from BALF of animals
administered killed bacteria. b) Macrophage and neutrophil concentrations obtained from
BALF of animals administered killed bacteria. (n=4-7) *p < 0.05, **p < 0.01, ***p < 0.001
vs. control; ###p < 0.001 vs. heat-killed bacteria.
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Figure 4.6
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Figure 4.6. Cytokine content in the BALF obtained from animals administered killed P.
aeruginosa. (n=5-7) *p < 0.05 vs. control; ##p < 0.01 vs. heat-killed.
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Figure 4.7
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Figure 4.8
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Figure 4.8. Cytokine content in the BALF obtained from animals administered killed S.
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4.4 Discussion
In the current study, the antimicrobial and anti-inflammatory effects of
BLES+CATH-2, a chicken cathelicidin suspended in a clinically-used exogenous
surfactant, were investigated as a potential therapeutic compound for the treatment of cystic
fibrosis. Here, we provided evidence that BLES+CATH-2 exhibits bactericidal activity
against an array of clinically derived pathogens from adult cystic fibrosis patients, as well
as being able to reduce the recruitment of inflammatory cells and modulate
proinflammatory cytokine production after heat-killed pathogens were instilled in vivo.
Taken together, the bactericidal and immunomodulatory properties of BLES+CATH-2
represent a potential therapy that warrants further investigation for the treatment of cystic
fibrosis lung infections.
The first goal of this study was to identify the bactericidal potential of
BLES+CATH-2 against multiple cystic fibrosis-associated bacterial isolates, including
multi-drug resistant isolates. P. aeruginosa represents one of the most prevalent bacteria
found in CF patients, while S. aureus is the most common bacteria in patients under the age
of 18 (8, 32–36). In addition to being the most common bacteria, these are also the most
drug-resistant bacteria isolated from CF patients, with reports of resistance rates as high as
22.6% and 42.7% against select antibiotics for both S. aureus and P. aeruginosa
respectively (37, 38). Consistent with this information, the multiple strains of P. aeruginosa
(including both mucoid and non-mucoid phenotypes), S. aureus, and A. xylosoxidans
isolated from CF patient sputum samples displayed a wide range of antibiotic resistance
patterns. Although the antimicrobial activity of BLES+CATH-2 against these clinical
strains was reduced compared to the CATH-2 peptide alone, BLES+CATH-2 exhibited
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significant antimicrobial activity at higher CATH-2 concentrations. At 100 µM peptide
concentrations, BLES+CATH-2 was able to reduce eight out of twelve bacterial isolates to
below detectable levels after three-hour incubations. For the remaining bacteria tested,
BLES+CATH-2 was still able to reduce bacteria by 3 log values for two of the four isolated
strains. This data was similar to what was previously observed when BLES+CATH-2 was
tested against other strains of P. aeruginosa or S. aureus (30). The concentration of 100
µM in the BLES+CATH-2 compound was the concentration previously used in safety and
tolerability studies in Chapter 2, suggesting that this concentration would be effective as
a therapeutic.
Interestingly, CATH-2 exhibited minimal bactericidal activity against S. aureus
when suspended in saline, but was significantly more active when the bacteria were
suspended in Müeller-Hinton broth. Previous groups have also shown this disparity in
activity, albeit during investigations of different peptides and different bacteria (39). They
determined that the key component of media that was responsible for these differences in
activity was carbonate, which appeared to increase bacterial susceptibility via alterations
in the membrane thickness. It is possible that similar changes occurred in this study, which
would explain the increased sensitivity of S. aureus to CATH-2, and the enhanced
antimicrobial activity of BLES+CATH-2 against both S. aureus and P. aeruginosa
suspended in MHB as opposed to saline. Importantly, it is suggested that the MHB media
conditions may be more accurate measures of antimicrobial activity. First, the Clinical and
Laboratory Standards Institute guidelines for investigations of antibiotic efficacy are
performed in MHB, and therefore our results presented here are directly applicable to
clinical investigation guidelines (40). Secondly, due to the carbonate and bicarbonate
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content found naturally within the lung, we believe that these media conditions are more
relevant to the in vivo environment, supporting the potential in vivo antimicrobial activity
of CATH-2 and BLES+CATH-2. Interestingly, as the CFTR is also a bicarbonate
transporter, and its loss of function leads to reduced bicarbonate concentrations in the airsurface liquid, it may help explain the diminished activity of endogenous host defense
systems observed in CF lung infections (41–43).
Following the bactericidal assays, we investigated whether the ability of CATH-2
to modulate inflammatory responses by killed bacteria was maintained after suspension in
the exogenous surfactant BLES. Two of the CF-isolated bacteria were killed ex vivo by
heat, before intratracheal administration. This specific experimental procedure was utilized
to specifically focus on the immunomodulatory properties of BLES+CATH-2 in response
to the bacterial products from clinical strains of bacteria. The data obtained provided
evidence that BLES+CATH-2 was capable of down-regulating inflammatory responses
induced by killed bacteria, and that the immunomodulatory activity occurred via an
antimicrobial-independent mechanism. This data is consistent with previous observations
obtained with CATH-2 alone utilizing a non-clinical strain of P. aeruginosa presented in
Chapter 3. The induction of inflammatory responses by heat-killed P. aeruginosa was
shown to be completely mitigated after co-treatment with BLES+CATH-2, as shown by
significant reductions in neutrophil influx, as well as reductions in all inflammatory
cytokines investigated, including KC (mouse analog of CXCL1) and MIP-2 (mouse analog
of CXCL2). This ability to not only kill clinically isolated antibiotic resistant bacteria, but
to also diminish the inflammatory response after killing provides a unique multi-functional
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therapeutic that would target two disease processes that are detrimental to CF patients (11,
32, 41, 42, 44).
Despite the profound anti-inflammatory activity of BLES+CATH-2 against heatkilled P. aeruginosa, the administration of identical concentrations of heat-killed S. aureus
produced a markedly different inflammatory response after intratracheal administration.
Heat-killed S. aureus administration lead to a significant increase in inflammatory cells in
the lavage, while co-treatment with both CATH-2 and BLES+CATH-2 significantly
reduced inflammatory cell infiltration, similar to results observed after administration of
heat-killed P. aeruginosa. Despite the increased neutrophil influx, no changes in cytokine
production induced by heat-killed S. aureus stimulation were observed. It is possible that
our method of heat-killing the bacteria induced significant changes to the
immunostimulatory products of S. aureus, such as lipoteichoic acid or the peptidoglycan
layer, as the lack of cytokines produced in this setting is inconsistent with previous studies
investigating TNF-α production by alveolar macrophages in vitro (45). An alternative
explanation for the lack of cytokine production observed in this study may be due to the
downregulation of virulence genes, including toxins and cell surface adhesion molecules,
which is commonly observed in CF patient-derived S. aureus isolates, therefore eliciting a
diminished inflammatory response (46–48).
It should be noted that, while the heat-killed bacteria model of inflammation used
is not entirely indicative of the clinical environment, we believe this to be a superior method
compared to instillation of single bacterial endotoxins, such as isolated lipopolysaccharide,
or other immune-stimulating bacterial toxins such as lipoteichoic acid, flagella, etc. This
method of inflammatory stimulation can account for a more relevant immune response, as
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it has previously been reported that the initial inflammatory response induced by heat-killed
bacteria is qualitatively similar to the response induced by live bacteria (49). In addition,
while many pathogen associated molecular patterns interact with specific pathogenrecognition receptors, whole bacteria will induce signalling and lead to changes in cytokine
expression through multiple pathways simultaneously (50). In the context of the current
experiment, this suggests that CATH-2, as well as BLES+CATH-2, has the ability to
interfere with multiple mechanisms of immune stimulation by bacteria, rather than via
blocking of one specific virulence factor (45, 49, 51, 52).
The use of exogenous surfactant as a vehicle to spread therapeutics throughout the
lung has been explored extensively, including the delivery of conventional antibiotics (27–
29, 53–56). It has the ability to increase therapeutic concentrations deposited in the airways
compared to aerosolized administration, as there is more uniform distribution and less
material lost in the central conducting airway regions during administration (26, 57).
Importantly, it also has the ability to bypass systemic administration, and reduces side
effects often associated with high circulating concentrations of antibiotics (58). For
cathelicidin peptides, this route of administration is especially important because of the
relatively short half life of most peptides (59, 60). While previous studies have
demonstrated that CATH-2 retains the most antimicrobial activity after suspension in the
exogenous surfactant BLES compared to other peptides (30), there are no studies
investigating the immunomodulatory activity of other cathelicidin peptides in BLES. If the
immunomodulatory activity is retained, despite antimicrobial activity loss, the cathelicidin
peptide library may become a crucial source for developing anti-inflammatory therapies
for respiratory disease, and warrants further investigation.
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In conclusion, we showed that the chicken cathelicidin CATH-2, in combination
with the exogenous surfactant BLES, possessed bactericidal activity against clinicallyderived antibiotic-resistant CF pathogens in vitro. In addition to this, we showed that
BLES+CATH-2 was able to downregulate inflammation through antimicrobialindependent mechanisms by silencing the inflammatory response induced by killed
bacteria. Taken together, the ability to kill multi-drug resistant bacteria and while being
able to modulate the hyper-inflammatory environment induced by these pathogens within
the CF patient airways provides strong evidence for the potential of BLES+CATH-2 as a
therapeutic for the management of respiratory infections associated with cystic fibrosis.
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Chapter 5: Efficacy of BLES+CATH-2 therapeutic
administration in in vivo models of bacterial pneumonia
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5.1 Introduction
Bacterial infection of the lungs, known as bacterial pneumonia, is the leading cause
of mortality due to bacterial infection, accounting for 35% of all deaths due to infectious
disease (1–3). While not always severe, approximately 24.8 cases per 10 000 adults with
community acquired pneumonia will be placed in intensive care units, with 6% of those
patients requiring mechanical ventilation (4). Pseudomonas aeruginosa is a common
bacterial pathogen associated with respiratory tract infection in immunocompromised
patients (5, 6). It is the second-leading cause of ventilator-associated pneumonia (VAP)
worldwide, and is associated with mortality rates as high as 90% after infection of
mechanically ventilated patients (7–10). Prevalence of antibiotic resistant infections has
been steadily increasing, with between 40-82% of hospital-acquired bacterial pneumonia
cases being caused by drug resistant infections (8). Indeed, P. aeruginosa resistance rates
are not exempt from this trend. The prevalence of multi-drug resistant and extensively drug
resistant isolates have steadily increased, and the rate of P. aeruginosa resistance towards
carbapenems, a class of “last resort” drugs, has significantly increased over the past decade,
with 34% of VAP isolates resistant to meropenem (10, 11). New treatment options are
desperately needed.
To develop a new therapy for the treatment of P. aeruginosa pneumonia, previous
work has identified a cathelicidin/surfactant combination that has shown effective
combined activity - specifically, the chicken cathelicidin CATH-2 in conjunction with
bovine lipid-extract surfactant (BLES). CATH-2 is one peptide that has been shown to
possess potent antimicrobial activity, and unlike many cathelicidins, is able to maintain this
activity in physiologically relevant salt conditions (12, 13). When suspended in BLES,
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BLES+CATH-2 has shown enhanced adsorptive and spreading properties compared to the
surfactant alone, whilst retaining the best bactericidal activity of all peptide/surfactant
combinations investigated as demonstrated in Chapter 2 (14). Chapter 4 presents
evidence of the therapeutic potential of this compound’s ability to kill multi-drug resistant
bacteria. However, BLES+CATH-2 activity in vivo has yet to be investigated. In this
chapter, we hypothesize that treatment with BLES+CATH-2 in animal models of bacterial
pneumonia will improve physiologic outcomes and increase bacterial clearance from the
airways.
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5.2 Materials and Methods
Bacterial Preparation
An overnight culture of P. aeruginosa ATCC 27853 was diluted 1/10 before optical
density was measured. The bacteria were then further diluted in either sterile saline for
mouse experimentation, or Müeller-Hinton Broth (MHB) for rat experiments, in order to
reach the initial concentration required for each individual experiment.

In vivo treatment of acute bacterial pneumonia
Male C57Bl/6 mice (Charles River, Sherbrooke, Qc, Canada), weighing 19-28 g,
were used for this experiment. All animal procedures were approved by the Animal Use
Subcommittee at the University of Western Ontario, and followed the approved guidelines
described by the Canadian Council of Animal Care. Mice were anesthetized by
intraperitoneal injection of ketamine (100-125 mg/kg body weight) and dexmedetomidine
(0.5 mg/kg BW), and then intratracheally intubated using a 20 G catheter, with the aid of a
fiber-optic stylet (BioLite intubation system for small rodents, BioTex, Inc., Houston,
Texas, USA). Once intubated, mice were infected with 50 µl of bacteria at a concentration
of 2x106 CFU/ml. Five minutes after bacterial administration, the mice were administered
50 µl of one of the following five treatments: a) air bolus; b) saline; c) BLES (20 mg
phospholipid/kgBW); d) CATH-2 (100 µM; 0.64 mg/kgBW); or e) BLES+CATH-2. Mice
were extubated following successful instillation and were subsequently injected with the
reversal agent for dexmedetomidine, Antisedan, and allowed to breathe spontaneously for
either four or eighteen hours. After, the mice were euthanized by IP injection of sodium
pentobarbital (110 mg/kgBW) and dissection of the descending aorta. The lungs were
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removed en bloc, and placed in 3 ml of sterile saline before homogenization using a PotterElvehjam homogenizer. Aliquots from the homogenized tissue were plated on modified
cetrimide agar plates, and colony enumeration was performed the following morning.

In vivo rat ventilator-associated pneumonia model
Sprague-Dawley rats (Charles River, Sherbrooke, QC, Canada) weighing between
330-435 g were used for this experiment. In brief, animals were anesthetized with a mixture
of ketamine:dexmedetomidine (80 mg/kgBW; 0.5 mg/kgBW). Once no toe-pinch response
was observed in the animals, they received a subcutaneous injection of the analgesic
buprenorphine (0.05 mg/kgBW), followed by an additional subcutaneous injection of
sensorcaine (bupivacaine HCL, 0.2 ml – 2.5%) in the ventral neck region at the site of
incision. The right and left jugular veins were exposed and catheterized with PE-50 tubing
in order to continuously infuse anesthetic (propofol, 5-20 mg/h), the neuromuscular blocker
Nimbex (cisatracurium besilate, 0.4 mg/hr), and sterile fluids (heparinized saline 1000
IU/l). One carotid artery was also exposed and catheterized in order to monitor heart rate,
blood pressure, and blood oxygenation levels, as well as allowing for additional sterile
fluids infusion. The trachea was then exposed, and intubated using a 14 G endotracheal
tube and secured using 2-0 ligatures. After recording initial hemodynamic measurements,
the rats were administered a bolus of Nimbex (0.4 mg/kgBW) and immediately placed on
a volume-cycled rodent ventilator (Harvard Instruments, St. Laurent, QC, Canada).
Mechanical ventilation was performed using 100% oxygen and a ventilation strategy that
was set at a tidal volume of 8 ml/kg BW, a respiratory rate of 54-60 bpm, and a positiveend expiratory pressure of 5 cmH2O.
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Throughout mechanical ventilation, airway pressures were monitored every 15
minutes using an airway pressure monitor (Sechrist Industries, Anaheim, USA), and blood
gas measurements were performed by ABL800. Fifteen minutes after being placed on
ventilation, a blood gas was collected as a baseline. Inclusion criteria required an arterial
oxygenation of 400 mmHg partial pressure of oxygen/fraction of inspired oxygen
(PaO2/FiO2).
After reaching inclusion criteria, the animals were infected intratracheally with P.
aeruginosa. As noted above, bacteria were diluted in MHB to reach an initial concentration
of ~1x109 CFU/ml, of which 500 µl was instilled intratracheally. After instillation, the
animals received 3 ml air bolus followed by a single breath-hold in order to optimize
bacterial distribution throughout the airways. The animals were then returned to mechanical
ventilation for one hour, with monitoring of hemodynamics and arterial blood gases. At
this time, the animals were briefly disconnected from the ventilator and randomized to
receive one of the following treatments: a) saline; b) BLES (20 mg phospholipid/kgBW);
c) CATH-2 (100 µM; 0.64 mg/kg BW); or d) BLES+CATH-2. After instillation, the
animals received 3 ml air bolus followed by a breath hold, similar to post-bacterial
instillation, and returned to the ventilator and monitored for three hours. At the end of
ventilation, the animals were euthanized by administration of a bolus of sodium
pentobarbital (110 mg/kgBW) via the catheterized jugular vein, followed by dissection of
the descending aorta.
From one cohort, the lungs, spleen, liver, and blood were collected for
homogenization. Tissues were suspended in various volumes of sterile saline (2 ml for
spleen, 3 ml for lung, and 10 ml for liver tissue) and homogenized using a Potter-Elvehjem
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homogenizing potter. The homogenate was then serially diluted and plated on cetrimide
agar plates and incubated overnight before performing colony enumeration the following
day.
In the second cohort, bronchoalveolar lavage fluid (BALF) was collected via whole
lung lavage as previously described (15). A sample of the BALF was serially diluted and
plated on cetrimide agar plates in order to perform colony enumeration. The remaining
BALF was then centrifuged at 150 g for 10 minutes. Supernatant was aliquoted for protein
content analysis and inflammatory cytokine concentrations. The remaining cell pellet was
suspended in 1 ml of PlasmaLyte, and diluted 100x. An aliquot of the diluted cell pellet
was mixed with an equal volume of trypan blue in order to perform total cell counts using
a hemocytometer and light microscopy. In addition, a 10x dilution of the cell pellets were
centrifuged onto cytospin slides at 1000 rpm for six minutes before staining with
Hemacolor stain (Harleco, EMD Chemicals Inc., Gibbstown, NJ, USA). Cell differentials
were then performed under light microscopy as previously described (16). Protein content
within the lavage fluid was determined using a Micro-BCA protein kit (Pierce, Rockford,
IL) according to the manufacturer’s instructions. IL-6 and TNF-α levels were measured
using respective enzyme-linked immunosorbent assay kits (ELISA kits; BD Biosciences,
San Diego, CA, USA) according to the manufacturer’s instructions.

Statistical Analysis
Statistical significance for the bactericidal activity of the various treatments in vivo
was determined using a one-way measure analysis of variance (ANOVA) followed by
Tukey’s post-hoc test. The effect of various treatments on peak inspiratory pressures and
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arterial oxygenation was assessed using a two-way ANOVA followed by Tukey’s post-hoc
test. Total cell counts, cell differentials, and inflammatory cytokine concentrations were
also analyzed by one-way ANOVA. Means are reported ± standard errors of the mean, and
values were determined to be significantly different at a probability value (p) < 0.05.
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5.3 Results
Bacterial recovery in mice
After intratracheal inoculation of ~2x106 CFU/ml of P. aeruginosa ATCC 27853,
mice were treated with a 50 µl intratracheal instillation of either CATH-2 (100 µM) or
BLES+CATH-2 (20 mg/kgBW phospholipid; 100 µM). Four hours after treatment,
bacterial recovery was significantly reduced from lung homogenate of animals treated with
BLES+CATH-2 compared to saline controls (Figure 5.1a). CATH-2 treatment alone
showed no significant effect on bacterial load in lung homogenate.
After 18 hours, all control treatment groups had a reduced bacterial recovery from
the lung homogenate, indicating bacterial clearance by the animals’ innate immune defense
system. The effect of BLES+CATH-2 administration was no longer observed 18 hours after
instillation, as there was no significant difference in bacterial recovery from lung
homogenate in animals treated with BLES+CATH-2 compared to any of the control
treatment groups (Figure 5.1b). In contrast, lung homogenate from animals administered
CATH-2 had a significantly increased bacterial load compared to all other treatment
groups.
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Figure 5.1. Bacterial recovery from lung tissue homogenate a) four hours, or b) eighteen
hours after administration of P. aeruginosa. (n=5-8) *p < 0.05 vs. saline treatment; +p <
0.05 vs. all treatment groups.
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Physiologic outcomes in ventilator-associated pneumonia model
In the rat VAP model, the animals were placed on mechanical ventilation using a
clinically relevant ventilation strategy (8 ml/kg BW tidal volume; 5 cmH2O positive end
expiratory pressure, 54-60 breaths per minute respiratory rate). After reaching inclusion
criteria of PaO2/FiO2 > 400 mmHg, the animals were inoculated with ~ 5x108 CFU of P.
aeruginosa ATCC 27853. One hour following bacterial administration, the animals were
administered treatments, and returned to the ventilator for three hours. Throughout
ventilation, peak airway pressure was recorded. Saline-treated animals showed a significant
increase in peak-inspiratory pressure (PIP) over the course of ventilation, indicative of
decreasing lung compliance and development of lung injury (Figure 5.2). CATH-2
instillation elicited a significant increase in PIP 15 minutes after instillation compared to
BLES alone, with no other significant differences observed. Similarly, CATH-2 treated
animals had significantly higher PIP values from 180 – 225-minute ventilation time points
compared to BLES+CATH-2.
In addition, arterial oxygenation was also measured over the course of ventilation.
For saline control treated animals, arterial oxygenation at the end of ventilation was reduced
compared to baseline measurements, with the mean oxygenation decreasing to 199 mmHg
by the end of ventilation, again indicating respiratory dysfunction (Figure 5.3). Animals
that received CATH-2 treatment presented a significant, severe drop in arterial oxygenation
immediately after administration (t60mins = 508.7 ± 15.12 mmHg; t75mins = 112.0 ± 16.73
mmHg). Arterial oxygenation at this time-point was significantly different to every other
treatment group, and CATH-2 treated animals showed significantly reduced oxygenation
compared to BLES treated animals throughout the remaining three hours of ventilation.
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After treatment, BLES+CATH-2-treated animals also showed a significant increase
in arterial oxygenation compared to CATH-2 treated animals throughout the course of
ventilation. However, there was no significant difference between BLES+CATH-2
treatment and either saline or BLES treatment (Figure 5.3). There was no significant
difference in mean arterial pressure, heart rate, or the arterial partial pressure of carbon
dioxide at any time point between any of the treatment groups. There was a significant
reduction of pH in animals receiving CATH-2 alone compared to all other treatment groups
at t = 75 mins (Table 5.1).
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Figure 5.2. Peak inspiratory pressure over the duration of ventilation. (n=17-18) xxp < 0.01
vs. BLES; +p < 0.05 vs. BLES+CATH-2.
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Figure 5.3
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Figure 5.3. Arterial oxygenation during mechanical ventilation. Bacterial instillation at t
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Treatment Group
Baseline
Mean Arterial Pressure (mmHg)
Saline
168.9 ± 6.78
BLES
161.9 ± 4.60
CATH-2
161.2 ± 4.89
BLES+CATH-2
168.8 ± 4.04
Heart Rate (bpm)
Saline
248.9 ± 5.13
BLES
238.9 ± 5.58
CATH-2
241.7 ± 6.75
BLES+CATH-2
243.2 ± 5.23
PaCO2 (mmHg)
Saline
45.07 ± 1.52
BLES
44.90 ± 2.08
CATH-2
43.80 ± 1.75
BLES+CATH-2
43.76 ± 1.50
pH
Saline
7.356 ± 0.001
BLES
7.349 ± 0.012
CATH-2
7.359 ± 0.011
BLES+CATH-2
7.350 ± 0.011

t=15

t=75

t=240

110 ± 5.60
112.6 ± 6.39
115.2 ± 3.63
109.0 ± 5.41

90.8 ± 5.41
83.7 ± 6.16
73.4 ± 2.92
81.78 ± 4.64

53.5 ± 2.60
47.82 ± 3.74
45.6 ± 3.74
51.0 ± 3.08

253.0 ± 4.19
252.4 ± 7.32
256.3 ± 2.99
250.8 ± 4.98

232.4 ± 5.13
223.6 ± 7.32
218.1 ± 6.86
220.0 ± 5.38

252.5 ± 6.02
252.2 ± 8.19
255.2 ± 8.19
249.9 ± 6.83

49.78 ± 1.34
48.39 ± 1.73
48.94 ± 1.77
49.22 ± 1.70

51.24 ± 1.79
51.15 ± 2.26
57.09 ± 2.50
50.12 ± 1.30

62.40 ± 3.48
58.09 ± 4.42
65.33 ± 4.81
56.66 ± 2.03

7.271 ± 0.009
7.273 ± 0.012
7.227 ± 0.014*
7.276 ± 0.010

7.122 ± 0.017
7.136 ± 0.022
7.107 ± 0.018
7.154 ± 0.012

7.312 ± 0.010
7.314 ± 0.011
7.313 ± 0.008
7.312 ± 0.011

Table 5.1. Physiologic measurements of rats through duration of mechanical ventilation.
(n=17-18) *p < 0.05 vs. all treatment groups.
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Bacterial Clearance and Immune Response
There was no significant difference in bacterial recovery between any treatment
group in both the whole lung homogenate (Figure 5.4a) or from the BALF (Figure 5.4b).
No significant difference in bacterial recovery was observed for any other tissues
investigated, such as spleen, liver, or serum (data not shown). Total cells recovered from
the BALF were not significantly different between treatment groups (Figure 5.5a). From
the total cells, the majority of cell types (>90%) recovered from all treatment groups were
neutrophils, however there was no significant difference in percentage of neutrophils
between any treatment groups (Figure 5.5b). There was no significant difference in total
protein content recovered from the BALF of any treatment group (Figure 5.5c). Cytokine
analysis from recovered BALF fluid also showed no significant difference in TNF-α
(Figure 5.5d).
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Figure 5.4. Bacterial recovery from a) lung tissue homogenate (n=9-11), or b) whole lung
BALF after ventilation (n=6-7).
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Figure 5.5.
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Figure 5.5. a) Total cell counts recovered from whole lung BALF, and b) percentage of
neutrophils from recovered cells. c) Total protein content recovered from BALF. d) TNFα content recovered from BALF. (n=4-7)
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5.4 Discussion
This study investigated the in vivo efficacy of BLES+CATH-2 as a treatment for
bacterial pneumonia. Two animal models were investigated in order to determine
BLES+CATH-2 bactericidal function against the clinically relevant pathogen P.
aeruginosa. In our spontaneously breathing mouse model, BLES+CATH-2 was able to
significantly reduce bacterial load from lung tissue four hours after intervention compared
to saline controls, although this significant difference was no longer observed 18 hours after
treatment. However, this bactericidal activity was not observed in the ventilator-associated
pneumonia rat model, as BLES+CATH-2 had no effect on bacterial recovery from the lung
tissue or bronchoalveolar lavage fluid. In addition, BLES+CATH-2 showed no significant
improvement in arterial oxygenation at the end of ventilation. Taken together, these results
demonstrate limited efficacy of BLES+CATH-2 after in vivo administration.
The rationale for this study was based in part on work described in Chapter 2,
which investigated the in vitro properties of the exogenous surfactant BLES with a panel
of different antimicrobial peptides (14). Throughout in vitro assays, it was identified that
the cathelicidin peptides interacted differently with BLES, and therefore activity was
modified as well. The most striking differences between peptides was their bactericidal
activity in vitro, where despite potent antibacterial activity of all four peptides, the addition
of BLES to mCRAMP and LL-37 completely abrogated all bactericidal function. On the
other hand, while CATH-2 activity was mitigated, it showed the greatest bactericidal
activity after suspension in BLES, and was therefore the most promising candidate for
investigating its in vivo bactericidal efficacy.
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Despite a plethora of studies to suggest bactericidal efficacy of cathelicidins in vitro,
data suggesting in vivo bactericidal activity is sparse (17, 18). Similar experimental models
using different cathelicidin peptides have previously failed to show any therapeutic benefit
(19). Other groups suggest that most cathelicidins, specifically LL-37 or mCRAMP, exert
their therapeutic role through the recruitment of neutrophils, and that the direct bactericidal
function of these peptides in negligible in vivo (20). It has been hypothesized that
environmental conditions and/or the short half-life of cathelicidins are responsible for this
lack of direct bactericidal activity in vivo (19, 21). In this study, we provide evidence that
BLES+CATH-2 may be able to exert some bactericidal activity, as shown through the
reduction in bacterial recovery from lung homogenate.
Previous studies performed in both Chapter 2 and Chapter 4 provided convincing
evidence of CATH-2 bactericidal potential in vitro, and moreover, that the addition of
BLES would actively reduce this antimicrobial activity. However, observations from this
study suggest that the bactericidal activity of CATH-2 and BLES+CATH-2 are much less
clear, as in our mouse pneumonia model, we observed a marginal decrease in bacterial
recovery from animals administered BLES+CATH-2, that was not observed from CATH2 treatment alone. This may in fact be due to the improved distribution and increase site
concentrations in these infection models, as hypothesized by the use of an exogenous
surfactant vehicle. The use of exogenous surfactant as a vehicle to spread therapeutics
throughout the lung has been explored extensively using conventional antibiotics (22–28).
Studies have shown that the use of exogenous surfactant as a vehicle has the potential to
increase the delivery efficiency of therapeutics to the lung over parenteral or intravenous
therapy (22, 26, 29–31). The four-hour acute pneumonia studies provide some evidence to
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suggest that BLES may be increasing the distribution of CATH-2 to the infection sites.
However, it appears that this increased spreading is not sufficient to significantly improve
bactericidal activity, as both the 18-hour pneumonia model and the VAP model showed no
reduction in bacterial recovery.
Expanding on the well-studied antimicrobial and immunomodulatory activity
throughout this thesis, this chapter also investigated the ability of BLES+CATH-2 to
improve arterial oxygenation, a clinically relevant outcome for patients placed on
mechanical ventilation (32). This study provides evidence that BLES+CATH-2 can
mediate a small improvement in arterial oxygenation, as animals administered
BLES+CATH-2 had an average increase of 77 mmHg compared to saline treated animals,
although this was not statistically significant. Additionally, this effect was also observed
by BLES treatment alone, which also improved oxygenation an average of 64 mmHg by
240 minutes, but again was not statistically significant. This data lends some support to the
hypothesis that the use of BLES can distribute throughout the lungs and into small
peripheral airways and alveoli, as previous work has suggested that this exogenous
surfactant administration is directly related to improved oxygenation (31, 33).
While both BLES and BLES+CATH-2 were able induce a mild improvement in
arterial oxygenation, CATH-2 treatment alone showed a significant deleterious effect. This
effect was most clearly observed in the VAP model, where despite a mild reduction in
bacterial recovery, CATH-2 administration caused a rapid and severe decrease in
oxygenation. This decrease was statistically lower than all other treatment groups between
time point 75 mins (immediately after treatment instillation) until the end of the ventilation
protocol. It is hypothesized that this drastic reduction is due to cytotoxic activity of CATH-
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2, leading to diffuse airway damage and decreasing oxygenation. The cytotoxic activity of
CATH-2 has been demonstrated in vitro via hemolytic assays, and we theorize that this
activity is the cause of the rapid decline in oxygenation (13). We expect that this is also the
reason behind the increased bacterial recovery observed at 18 hours in the mouse, where
increased epithelial damage would improve bacterial colonization and proliferation.
However, we could not detect any differences in protein content or inflammatory cytokines
within the BALF, which would be expected in the case of severe epithelial cell death, and
therefore further studies to confirm these observations are required. Importantly,
BLES+CATH-2 administration did not induce any of these deleterious changes, indicating
greater safety and tolerability of administration, even though data supporting any
therapeutic benefit is currently lacking.
As mentioned, this chapter is the first investigation of direct bactericidal activity,
and ability to affect clinically relevant outcomes, in two separate in vivo animal models. In
this chapter, we utilized a well-described model of acute bacterial pneumonia in a C57Bl/6
mouse, and a rat VAP model using Sprague-Dawley rats. The mouse model investigated
here has previously been used to study the effect of exogenous cathelicidin administration
for the treatment of P. aeruginosa respiratory infection (20). However, whereas previous
studies collected BALF and measured cell recruitment and cytokine production, our initial
studies solely investigated bacterial recovery, and were therefore limited by the use of
tissue homogenate instead of lavage fluid analysis. In order to expand on these initial
studies, the VAP-rat was used to collect and analyze both tissue homogenate and BALF
rather than the mouse pneumonia model. This second model was selected for two reasons:
1) a significantly greater volume of BALF is available in rats, and 2) we are able to measure
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peak-inspiratory pressure, arterial oxygenation, and a number of other clinically-relevant
parameters in the VAP model that were unavailable in the mouse pneumonia model. Thus,
the inclusion of the VAP model permitted a greater range of outcome measurements. In
addition, this study provided the opportunity to investigate the therapeutic potential of
BLES+CATH-2 in severe lung dysfunction and inflammation settings, as noted by
decreased oxygenation, and increased inflammatory cytokine production. Taken together,
these two models were able to provide substantial data towards the efficacy of
BLES+CATH-2 treatment in separate in vivo pneumonia models.
However, despite the large amount of data acquired from these models, there are
many limitations of study. The first issue involves the use of P. aeruginosa as our bacterial
model of infection. It has been well documented that, in healthy animal models, P.
aeruginosa can be readily cleared by the host immune system (34). This is the likely
explanation for why there was such a large reduction in bacterial recovery 18 hours after
administration in the mouse pneumonia model regardless of treatment. Similar limitations
were observed in the rat VAP model, as rats clear P. aeruginosa even more efficiently than
mice (34). To this effect, preliminary studies performed in collaboration with Dr. Nicholson
identified the bacterial load required to develop a respiratory infection that caused a
significant reduction in arterial oxygenation over the course of ventilation, without the
innate clearance of the bacteria. The resulting data suggested that the rat VAP model
required a much larger bacterial load to develop signs of lung injury during infection than
the acute pneumonia model used in mice. It is possible that this large dose was the reason
why no bactericidal activity of BLES+CATH-2 was observed in this model, a phenomena
known as the “inoculum effect”, in which antibiotics lose potency as bacterial load
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increases (35). In future, animal models should utilize different strategies for infection, in
order to more accurately model development of bacterial pneumonia. Use of different
animal/bacteria combinations, would better describe the progression of a respiratory
infection and development of chronic disease states, which more accurately represents the
situation in clinical settings and would better predict the efficacy of therapeutic treatments
against these infections (10, 36–40). Animal models that are administered multiple
therapeutic doses would also be more viable for future testing, as again these would be
more accurate of the treatment regimens currently prescribed (41–44).
In conclusion, this study presented evidence that BLES+CATH-2 can exhibit some
bactericidal activity in vivo as observed in the mouse model of acute bacterial pneumonia,
which showed a significant reduction in bacterial recovery four hours after instillation
compared to control treatments, and lead to a mild improvement in oxygenation in VAP
models compared to saline controls, although there was no statistically significant
difference between these treatment groups. Moreover, while CATH-2 appeared to induce
detrimental effects after administration, none of the negative outcomes were observed after
BLES+CATH-2 treatment, suggesting safety and tolerability of this compound. While we
were unable to identify any statistically significant improvement to clinical outcomes in
both of our infection models, this was the first study to investigate the activity of
BLES+CATH-2 in vivo, and supports the conclusions that BLES+CATH-2 does not induce
harmful side effects after administration. Future studies will be required in order to improve
BLES+CATH-2 therapeutic activity in vivo, via increased bacterial clearance and improved
arterial oxygenation, without sacrificing compound tolerability.
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Chapter 6: Summary and discussion of major findings
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The objective of this thesis was to develop and investigate the therapeutic potential
of a cathelicidin peptide/exogenous surfactant compound mixture for the treatment of
bacterial pneumonia. The high incidence of bacterial pneumonia, coupled with the
increasing prevalence and global health crisis of multi-drug resistant infections, was the
rationale for our pursuit of therapeutic development (1, 2).
Our hypothesis was that the use of cathelicidin peptides (multifunctional peptides
with potent antimicrobial activity and immunomodulatory properties) in combination with
exogenous pulmonary surfactant (which is able to spread rapidly throughout the airways,
with improved deposition compared to aerosol administration) would improve outcomes in
bacterial

pneumonia.

Throughout

this

thesis,

we

developed

and

tested

a

cathelicidin/surfactant compound for it’s ability to a) maintain biophysical activity, b)
provide antibacterial activity, c) modulate the inflammatory response during stimulation by
dead bacteria, and finally d) investigating the antibacterial, immunomodulatory, and
physiologic benefit of BLES+CATH-2 in in vivo models of pneumonia.
Initially, we investigated the properties of various cathelicidins with the exogenous
surfactant BLES to select an optimal cathelicidin/surfactant combination in Chapter 2. By
investigating the biophysical properties of the surfactant with various cathelicidin peptides,
we observed that the four cathelicidin peptides tested had minimal effect on biophysical
function, i.e. the ability to reduce surface tension upon lateral compression. When
investigating the adsorptive properties of these cathelicidin/surfactant combinations, we
observed that cathelicidins enhanced diffusion in a dose-dependent manner. We theorized
that this increased adsorption was caused by the cathelicidins’ ability to interact with and
“break” the surfactant bilayers in the aqueous subphase, increasing surfactant material
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released and available to move to the air-liquid interface. The surfactant protein SP-C,
which is relatively similar to cathelicidins in structure, is crucial for surfactant adsorption
(3, 4). It is possible that cathelicidins interact with the surfactant phospholipids through a
similar mechanism, which would explain the phenomena observed in this thesis.
In addition to these findings, we also discovered that bactericidal activity of
cathelicidins was severely impaired when mixed with surfactant. Due to the cationic nature
of cathelicidins, and the presence of anionic phospholipids, such as PG, we theorize that
this reduced activity is due to electrostatic interactions of the peptides with PG, “masking”
the cationic charge of the peptide and preventing the interaction with bacterial membranes.
These results were verified when investigating BLES+CATH-2 activity against MDRisolates obtained from CF patients in Chapter 4. However, the degree of inhibition appears
to be cathelicidin dependent; while CATH-2 and CATH-1 still maintained some
bactericidal activity, LL-37 and mCRAMP completely lost antimicrobial functions. It is
possible

that,

due

to

different

peptide

structures,

different

cathelicidin

interactions/orientations within the phospholipid membranes may differ the charge
masking, as previously observed (5–7). This would allow peptides such as CATH-2 (with
two α-helical regions, both containing basic amino acid residues) to maintain some
interaction with bacterial membranes, while other peptides (i.e. LL-37, with a single αhelical region that spans the majority of the peptide) insert deeper inside the membrane,
and completely mask antimicrobial activity. In all, the key conclusions to be drawn from
these results is that a) BLES+CATH-2 shows the most potent bactericidal properties of all
cathelicidin/surfactant combinations tested to date, and b) that this compound retains
bactericidal activity against MDR-clinical isolates.
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While BLES+CATH-2 showed the most potent bactericidal activity, the
immunomodulatory activity of CATH-2, as well as BLES+CATH-2, was relatively
unknown. Unpublished results from our lab, as well as from our collaborator Dr. Coorens
at Utrecht University demonstrated that, in vitro, CATH-2 and BLES+CATH-2 were able
to prevent pro-inflammatory cytokine production from macrophages after treatment with
either LPS or killed bacteria. These studies are supported by a wealth of data about other
cathelicidin peptides, which suggest that one of the endogenous functions of cathelicidins
is to downregulate inflammatory signalling by bacterial toxins, such as LPS (8–11).
To expand on this, Chapter 3 and Chapter 4 investigated whether CATH-2 and
BLES+CATH-2 could provide this anti-inflammatory activity with killed bacteria in vivo.
Instillation of heat-killed bacteria, which has previously been used to study inflammatory
responses (12–14), were used to focus solely on CATH-2 immunomodulatory activity. The
benefit of this model over instillation of a single bacterial PAMP (i.e. LPS or LTA) was the
presence of multiple immunogenic compounds able to activate multiple different PAMP
receptors and signalling pathways simultaneously. In these studies, the co-treatment of
CATH-2 or BLES+CATH-2 with heat-killed P. aeruginosa, including both ATCC strains
and MDR-clinical isolates, were able to reduce inflammatory cytokine production to
concentrations equal to naïve and control treatment groups. These studies present evidence
that CATH-2, and importantly BLES+CATH-2, can prevent and/or reduce the
inflammation elicited by killed bacteria.
On top of the ability of CATH-2/BLES+CATH-2 to modulate inflammatory
responses, Chapter 3 demonstrated that bacteria killed by CATH-2 did not induce any
inflammatory response. This activity, termed “silent killing”, was initially presented by Dr.
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Coorens in vitro, and showed that the cathelicidin peptide CATH-2 was able to kill bacteria
in co-cultures with macrophages without inducing an inflammatory response (15). These
results were expanded to the in vivo setting, which demonstrated that CATH-2-killed
bacteria did not induce an inflammatory response in the airways after intratracheal
instillation. Animals that received CATH-2-killed bacteria, similar to heat-killed bacteria
co-treated with CATH-2 or BLES+CATH-2, has less inflammatory cells recovered from
the BALF, and reduced cytokine concentrations in BALF. This “silent” killing mechanism
has vast therapeutic potential moving forward, as the ability to kill bacteria without eliciting
an inflammatory response would greatly increase recovery time, and limit the collateral
tissue damage caused by inflammatory cell migration and activation.
However, treatment of VAP with BLES+CATH-2 showed no beneficial effects in
Chapter 5. Indeed, while treatment in the mouse acute pneumonia model showed a
significant difference between saline-controls and BLES+CATH-2 treatment, this
bactericidal activity was not observed in the rat VAP model. While treatment with
BLES+CATH-2 significantly increased oxygenation in this model compared to CATH-2
alone, there was no significant improvement over saline or BLES controls. In all, it appears
that BLES+CATH-2 was an ineffective therapeutic for P. aeruginosa induced VAP in our
rat model.
Based on the data accumulated throughout this thesis project, we conclude that
BLES+CATH-2 has some therapeutic potential for the treatment of multi-drug resistant
bacterial pneumonia. However, the lack of antimicrobial activity demonstrated in vivo
suggests that further research is needed in order to improve BLES+CATH-2 activity. The
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purpose of this chapter is to discuss potential future directions in order to continue
development and improve the efficacy of BLES+CATH-2 as a therapeutic compound.

6.1 Future Directions
6.1.1 Alterations to exogenous surfactant composition
As described in Chapter 2, we theorize that the cause of the mitigated bactericidal
activity of BLES+CATH-2 involves the electrostatic interactions between the highly
cationic CATH-2 and anionic phospholipid PG in BLES. As such, one method to improve
the bactericidal activity of BLES+CATH-2 would be to reduce the content of anionic
phospholipids in the surfactant, freeing more cathelicidin peptide to interact with bacterial
membrane.
Previous work has gone into great detail over the orientation of cathelicidin peptides
in lipid membranes with different phospholipid content (5–7). From this, and from our
observations with cathelicidin peptides and the exogenous surfactant BLES, we
hypothesize that a reduction in PG content would reduce any electrostatic activity with the
cathelicidin peptide, without sacrificing surfactant biophysical properties. Indeed, many
natural surfactants and synthetic surfactants have varying phospholipid concentrations,
with PG content ranging anywhere between 20% (15) to as low as 7% found in endogenous
rabbit surfactant (16). By reducing the content of the acidic phospholipids in BLES from
~10% to as low as 5-7%, we hypothesize that we would be able to increase natural
cathelicidin activity (i.e. bactericidal function), without significant alterations to surfactant
spreading or biophysical function. However, future testing is required to determine if this
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hypothesis is correct, and if this would improve the therapeutic viability of a modified
surfactant + CATH-2.
One experimental approach to investigate this would be to formulate a synthetic
surfactant. With the addition of recombinant surfactant proteins, this synthetic surfactant
could be produced with a specific phospholipid composition aimed at improving the
interactions between the surfactant and the antimicrobial peptide to optimize antimicrobial
and immunomodulatory functions in vivo. This new surfactant could then be re-investigated
using the protocols described in this thesis to determine biophysical properties,
antimicrobial activities, immunomodulatory functions, and in vivo efficacy. Using
throughput screening of different surfactant compositions and cathelicidin peptides, we
anticipate that a surfactant/cathelicidin compound could be identified and developed as a
suitable therapeutic.

6.1.2 Focus on development of anti-inflammatory therapeutic
In lieu of the strong anti-inflammatory activity shown by BLES+CATH-2 in
Chapter 3 and Chapter 4, our lab has continued focus on investigating these properties of
BLES+CATH-2. Unlike the antimicrobial activity, BLES+CATH-2 appears to exhibit
much more consistent immunomodulatory activity. Work recently performed by an
undergraduate student, Christina Arsenault, showed that both CATH-2 and BLES+CATH2 was able to downregulate inflammatory responses after co-administration with heat-killed
P. aeruginosa, similar to results observed in Chapter 4. However, in addition, Ms.
Arsenault showed that after a 15-minute delay in administration (i.e. instillation of
treatment 15 minutes after instillation of heat-killed bacteria), CATH-2 lost its anti-
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inflammatory properties, while BLES+CATH-2 treated animals showed reduced
inflammatory cytokine production and cell infiltration.
In addition to this, more work done by a graduate student, Brandon Baer, has
continued these investigations by re-visiting the combined therapy of CATH-2 and
conventional antibiotics. Mr. Baer has identified that bacteria killed by a lower, more
clinically relevant dose of gentamicin than what was used in Chapter 3 (8 µg/ml vs. 1
mg/ml in Chapter 3) still elicit an inflammatory response similar to what was described in
this thesis. However, unlike previous results, the addition of CATH-2 did once again reduce
the production of inflammatory cytokines. Adding to the potential anti-inflammatory
activity of CATH-2, Mr. Baer has revisited other cathelicidin peptides, including LL-37
and PMAP-23, which showed that these anti-inflammatory properties appear to be
relatively well conserved across multiple different peptides.
This data, combined with the work performed by Ms. Arsenault, provides a
rationale for investigating the immunomodulatory activity of different cathelicidin peptides
with the exogenous surfactant BLES. The anti-inflammatory activities of cathelicidin
peptides, when administered with antibiotic-killed bacteria, presents a unique avenue for
therapeutic development in order to manage inflammation post-infection. In addition, the
supplementation of BLES appears to have a significant therapeutic benefit to this
immunomodulatory activity, and if this beneficial effect is conserved with other peptides,
it would vastly increase the library of therapeutic agents available for clinical development
and use. Therefore, there is a strong rationale to continue investigations into the
immunomodulatory activity of different cathelicidin peptides/exogenous surfactant is to
increase understanding of the therapeutic benefit of these compounds. The use of a various
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animal models to investigate multiple different mechanisms of lung inflammation, such as
asthma or chronic obstructive pulmonary disease, would allow for a thorough, robust
investigation to the limits and potential of BLES+CATH-2 as a respiratory antiinflammatory treatment.

6.2 Concluding Remarks
The presence of multi-drug resistant infections is the largest global health concern
facing this generation, and without the development of new therapies and practices, will
become the leading cause of death worldwide by 2050 (2). The high prevalence of bacterial
pneumonia, makes development of therapeutics specifically for respiratory tract infections
especially important.
Cathelicidin peptides are a unique source of development for future therapeutics for
respiratory infections. Their combined microbicidal activities and immunomodulatory
properties give these peptides a vast diversity of potential uses. The combined treatment
strategy of a cathelicidin peptide with exogenous surfactant, ideal to spread the peptides
throughout the complex lung structure, was investigated in this thesis. While the proof-ofprinciple determined the validity of this approach in vitro, the lack of antimicrobial activity
and physiologic improvements in in vivo models limits the potential of this compound.
Instead, anti-inflammatory activity was much more well defined, and may represent another
avenue for BLES+CATH-2 therapeutic development.
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